{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:13:55Z","timestamp":1793211235952,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd003407.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2012,12,12]],"date-time":"2012-12-12T00:00:00Z","timestamp":1355270400000}}],"reference-count":692,"publisher":"Wiley","issue":"12","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd003407.pub5","type":"journal-article","created":{"date-parts":[[2012,12,6]],"date-time":"2012-12-06T18:52:23Z","timestamp":1354819943000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":85,"title":["Erythropoietin or darbepoetin for patients with cancer"],"prefix":"10.1002","volume":"2012","author":[{"given":"Thomy","family":"Tonia","sequence":"first","affiliation":[{"name":"University of Bern; Institute of Social and Preventive Medicine; Bern Switzerland 3012"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Mettler","sequence":"additional","affiliation":[{"name":"University of Bern; Institute of Social and Preventive Medicine; Bern Switzerland 3012"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nad\u00e8ge","family":"Robert","sequence":"additional","affiliation":[{"name":"Kantonsspitalapotheke Winterthur; Pharmacy; Brauerstrasse 15 Winterthur Switzerland CH-8400"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Schwarzer","sequence":"additional","affiliation":[{"name":"Institute of Medical Biometry and Medical Informatics, University Medical Center Freiburg; German Cochrane Centre; Stefan-Meier-Str. 26 Freiburg Germany D-79104"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Seidenfeld","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology; Department of Quality and Guidelines; 1900 Duke Street, Suite 200 Alexandria VA USA 22314"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Weingart","sequence":"additional","affiliation":[{"name":"Achterstreet 11 Cologne Germany 50678"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Hyde","sequence":"additional","affiliation":[{"name":"University of Exeter Medical School, University of Exeter; Peninsula Technology Assessment Group (PenTAG); Veysey Building Salmon Pool Lane Exeter UK EX2 4SG"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Engert","sequence":"additional","affiliation":[{"name":"University Hospital of Cologne; Cochrane Haematological Malignancies Group, Department I of Internal Medicine; Kerpener Str. 62 Cologne Germany 50924"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Bohlius","sequence":"additional","affiliation":[{"name":"University of Bern; Institute of Social and Preventive Medicine; Bern Switzerland 3012"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,12,12]]},"reference":[{"key":"10.1002\/14651858.CD003407.pub5-BIB0001|cit1","unstructured":"Aapro M Barnadas A Leonard RC Marangolo M Untch M Effects of epoetin beta treatment in patients with metastatic breast cancer receiving chemotherapy. Results of the BRAVE trial Breast Cancer Research and Treatment 2006 abstract 6095"},{"issue":"4","key":"10.1002\/14651858.CD003407.pub5-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1200\/JCO.2007.11.5378","article-title":"Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and\/or taxane-based chemotherapy: Results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) Study","volume":"26","author":"Aapro","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD003407.pub5-BIB0003|cit3","first-page":"iii.50 (Abstrac","article-title":"Once weekly epoetin beta in patients with metastatic breast cancer receiving anthracycline- or taxane-based chemotherapy","volume":"Vol. 15","author":"Leonard","year":"2004","journal-title":"Annals of Oncology"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0004|cit4","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003407.pub5-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0959-8049(05)80281-3","article-title":"Erythropoietin for anemia in cancer patients","volume":"29A","author":"Abels","year":"1993","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000204780","article-title":"Recombinant human erythropoietin in the treatment of the anaemia of cancer","volume":"87 (Suppl 1)","author":"Abels","year":"1992","journal-title":"Acta Haematologica"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1634\/theoncologist.1-3-140","article-title":"Recombinant Human Erythropoietin (rHuEPO) for the treatment of the anemia of cancer","volume":"1","author":"Abels","year":"1996","journal-title":"Oncologist"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0008|cit8","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0009|cit9","unstructured":"Johnson & Johnson Pharmaceutical Research & Development L.L.C Background information for Oncologic Drugs Advisory Committee Meeting, Safety of Erythropoietin Receptor Agonists (ERAs) in Patients with Cancer Johnson and Johnson briefing document for FDA\/ODAC hearing May 4, 2004; Gaithersburg, MD,"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0010|cit10","unstructured":"Antonadou D Cardamakis E Puglisi M Malamos N Throuvalas N Erythropoietin enhances radiation treatment efficacy in patients with pelvic malignancies. Final results of a randomized phase III study Poster"},{"issue":"2","key":"10.1002\/14651858.CD003407.pub5-BIB0011|cit11","first-page":"127","article-title":"Recombinant human erythropoietin for platinum-based chemotherapy-induced anaemia: A single-centre randomised study","volume":"8","author":"Aravantinos","year":"2003","journal-title":"Journal of B U On"},{"issue":"2","key":"10.1002\/14651858.CD003407.pub5-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000067766","article-title":"Prevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by recombinant human Erythropoietin (rHuEpo): a prospective, open label, randomized trial by the Hellenic Cooperative Oncology Group","volume":"64","author":"Bamias","year":"2003","journal-title":"Oncology"},{"issue":"28","key":"10.1002\/14651858.CD003407.pub5-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1200\/JCO.2010.30.4899","article-title":"Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study","volume":"29","author":"Blohmer","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0014|cit14","unstructured":"Blohmer JU Wuerschmidt J Petry K Weise G Sehouli J Kimming R Results with sequential adjuvant chemo-radiotherapy with vs. without epoetin alfa for patients with high-risk cervical cancer: results of a prospective, randomized, open and controlled AGO and NOGGO-intergroup study Annals of Oncology. Vol. 15 Suppl 3 2004"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0016|cit15","unstructured":"Neorecormon (epoetin beta) Briefing package or the FDA Oncologic Advisory Committee Meeting, May 4, 2004"},{"issue":"7","key":"10.1002\/14651858.CD003407.pub5-BIB0015|cit16","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/sj.bjc.6600801","article-title":"Impact of epoetin beta on quality of life in patients with malignant disease","volume":"88","author":"Boogaerts","year":"2003","journal-title":"British Journal of Cancer"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0017|cit17","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0018|cit18","unstructured":"Coiffier B Boogaerts M Kainz C Impact of epoetin beta on quality of life in patients with malignant disease 6th Congress of the European Haematology Association 2001 Abstract #194"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0019|cit19","first-page":"596a. Abstract","article-title":"Epoetin alfa in the prevention of anemia in cancer patients undergoing platinum-based chemotherapy (CT) (CT). A prospective randomized study","volume":"18","author":"Carabantes","year":"1999","journal-title":"Proceedings of the American Society of Clinical Oncology"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1200\/JCO.1994.12.5.1058","article-title":"Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo","volume":"12","author":"Cascinu","year":"1994","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1634\/theoncologist.1-3-140","article-title":"Recombinant Human Erythropoietin (rHuEPO) for the treatment of the anemia of cancer","volume":"1","author":"Abels","year":"1996","journal-title":"Oncologist"},{"issue":"10","key":"10.1002\/14651858.CD003407.pub5-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/jnci\/85.10.801","article-title":"Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy","volume":"85","author":"Case","year":"1993","journal-title":"Journal of the National Cancer Institute"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0023|cit23","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0024|cit24","unstructured":"Johnson & Johnson Pharmaceutical Research & Development L.L.C Background information for Oncologic Drugs Advisory Committee Meeting, Safety of Erythropoietin Receptor Agonists (ERAs) in Patients with Cancer Johnson and Johnson briefing document for FDA\/ODAC hearing May 4, 2004; Gaithersburg, MD,"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0026|cit25","unstructured":"Neorecormon (epoetin beta) Briefing package or the FDA Oncologic Advisory Committee Meeting, May 4, 2004"},{"issue":"12","key":"10.1002\/14651858.CD003407.pub5-BIB0025|cit26","doi-asserted-by":"crossref","first-page":"4446","DOI":"10.1182\/blood.V86.12.4446.bloodjournal86124446","article-title":"Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response","volume":"86","author":"Cazzola","year":"1995","journal-title":"Blood"},{"issue":"12","key":"10.1002\/14651858.CD003407.pub5-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"4446","DOI":"10.1182\/blood.V86.12.4446.bloodjournal86124446","article-title":"Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response","volume":"86","author":"Cazzola","year":"1995","journal-title":"Blood"},{"issue":"12","key":"10.1002\/14651858.CD003407.pub5-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"4446","DOI":"10.1182\/blood.V86.12.4446.bloodjournal86124446","article-title":"Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response","volume":"86","author":"Cazzola","year":"1995","journal-title":"Blood"},{"issue":"12","key":"10.1002\/14651858.CD003407.pub5-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"4446","DOI":"10.1182\/blood.V86.12.4446.bloodjournal86124446","article-title":"Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response","volume":"86","author":"Cazzola","year":"1995","journal-title":"Blood"},{"issue":"12","key":"10.1002\/14651858.CD003407.pub5-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"4446","DOI":"10.1182\/blood.V86.12.4446.bloodjournal86124446","article-title":"Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response","volume":"86","author":"Cazzola","year":"1995","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0031|cit31","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"12","key":"10.1002\/14651858.CD003407.pub5-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1200\/JCO.2004.12.027","article-title":"Once weekly epoetin alfa maintains hemoglobin, improves quality of life and reduces transfusion in breast cancer patients receiving chemotherapy","volume":"23","author":"Chang","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD003407.pub5-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3816\/SCT.2004.n.023","article-title":"Weekly administration of epoetin alfa improves cognition and quality of life in patients with breast cancer receiving chemotherapy","volume":"2","author":"Chang","year":"2004","journal-title":"Supportive Cancer Therapy"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0034|cit34","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0035|cit35","doi-asserted-by":"crossref","unstructured":"Charu V Belani CP Gill AN Bhatt M Ben-Jacob A Tomita D A controlled, randomized, open-label study to evaluate the effect of every-2-week darbepoetin alfa for anemia of cancer Annual Meeting Proceedings of the American Society of Clinical Oncology 2004 abstract 8084","DOI":"10.1200\/jco.2004.22.14_suppl.8084"},{"issue":"6","key":"10.1002\/14651858.CD003407.pub5-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1634\/theoncologist.12-6-727","article-title":"Efficacy and safety of every-2-week darbepoetin alfa in patients with anemia of cancer: a controlled, randomized, open-label phase II trial","volume":"12","author":"Charu","year":"2007","journal-title":"Oncologist"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD003407.pub5-BIB0037|cit37","first-page":"14","article-title":"Improvements in fatigue are associated with early treatment with darbepoetin alfa every 3 weeks in anemic patients receiving chemotherapy","volume":"3","author":"Charu","year":"2005","journal-title":"The Journal of Supportive Oncology"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0038|cit38","unstructured":"Amgen Inc with contributions from Johnson & Johnson Pharmaceutical Research and Development L.L.C Safety of Erythropoiesis-Stimulating Agents (ESAs) in Oncology) Background information for Oncologic Drugs Advisory Committee 10 May 2007"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0039|cit39","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0040|cit40","first-page":"693","article-title":"Effects of epoetin-alpha on quality of life of cancer patients with solid tumors receiving chemotherapy","volume":"29","author":"Christodoulou","year":"2009","journal-title":"Anticancer Research"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0041|cit41","unstructured":"Janinis J Dafni U Aravantinos G Kalofonos HP Papakostas P Tsavdaridis D Quality of life (QoL) outcome of epoietin-alfa (EPO-A) in anemic cancer patients undergoing platinum or non-platinum-based chemotherapy: a randomized study conducted by the Hellenic Cooperative Oncology Group Proceedings of the American Society of Clinical Oncology 2003 789"},{"issue":"1","key":"10.1002\/14651858.CD003407.pub5-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1046\/j.1365-2141.2001.02715.x","article-title":"Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma","volume":"113","author":"Dammacco","year":"2001","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s005990050032","article-title":"The effectiveness and tolerability of epoetin alfa in patients with multiple myeloma refractory to chemotherapy","volume":"28","author":"Dammacco","year":"1998","journal-title":"International Journal of Clinical and Laboratory Research"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0044|cit44","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0045|cit45","unstructured":"Johnson & Johnson Pharmaceutical Research & Development L.L.C Background information for Oncologic Drugs Advisory Committee Meeting, Safety of Erythropoietin Receptor Agonists (ERAs) in Patients with Cancer Johnson and Johnson briefing document for FDA\/ODAC hearing May 4, 2004; Gaithersburg, MD,"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0046|cit46","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0047|cit47","doi-asserted-by":"crossref","unstructured":"Debus J Hindermann S Morr H Mezger J Sebastian M Angermund R Epoetin alfa (EPO) and survival in patients with non-resectable NSCLC - Interim results Lung Cancer 2005 S57","DOI":"10.1016\/S0169-5002(05)81040-2"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0048|cit48","unstructured":"Johnson & Johnson Pharmaceutical Research & Development L.L.C Background information for Oncologic Drugs Advisory Committee Meeting, Safety of Erythropoietin Receptor Agonists (ERAs) in Patients with Cancer Johnson and Johnson briefing document for FDA\/ODAC hearing May 4, 2004; Gaithersburg, MD,"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0049|cit49","doi-asserted-by":"crossref","unstructured":"Debus J Hindermann S Morr H Mezger J Sebastian M Angermund R Epoetin alfa (EPO) and survival in patients with non-resectable NSCLC - Interim results Lung Cancer 2005 S57","DOI":"10.1016\/S0169-5002(05)81040-2"},{"issue":"7","key":"10.1002\/14651858.CD003407.pub5-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1200\/JCO.1997.15.7.2715","article-title":"Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia","volume":"15","author":"Mastro","year":"1997","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1362::AID-CNCR36>3.0.CO;2-T","article-title":"Erythropoietin reduces anemia and transfusions","volume":"86","author":"Dunphy","year":"1999","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0052|cit52","first-page":"2598","article-title":"Prospetively randomized placebo-controlled trial of epoetin-alfa in patients with advanced-stage Hodgking lymphoma: final analysis of the GHSG HD15-EPO trial","volume":"112","author":"Engert","year":"2008","journal-title":"Blood ASH Annual Meeting Abstracts"},{"issue":"13","key":"10.1002\/14651858.CD003407.pub5-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1200\/JCO.2009.25.1835","article-title":"Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial","volume":"28","author":"Engert","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0054|cit54","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0055|cit55","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0056|cit56","unstructured":"Johnson & Johnson Pharmaceutical Research & Development L.L.C Background information for Oncologic Drugs Advisory Committee Meeting, Safety of Erythropoietin Receptor Agonists (ERAs) in Patients with Cancer Johnson and Johnson briefing document for FDA\/ODAC hearing May 4, 2004; Gaithersburg, MD,"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0057|cit57","unstructured":"Luksenburg H Weir A Wager R EPO-INT-1: Safety Concerns Associated with Aranesp (darbepoetin alfa) Amgen, Inc. and Procrit (epoetin alfa) Ortho Biotech, L.P., for the Treatment of Anemia Associated with Cancer Chemotherapy Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Oncologic Drugs Advisory Committee, Rockville (MD), USA, 2004"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0058|cit58","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0059|cit59","unstructured":"A placebo controlled study on the effect of r-HeUPO in patients with malignancy receiving chemotherapy.Study: CR005923 Raritan, NJ: RW Johnson Pharmaceutical Research Institute 1998"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0060|cit60","unstructured":"Johnson & Johnson Pharmaceutical Research & Development L.L.C Background information for Oncologic Drugs Advisory Committee Meeting, Safety of Erythropoietin Receptor Agonists (ERAs) in Patients with Cancer Johnson and Johnson briefing document for FDA\/ODAC hearing May 4, 2004; Gaithersburg, MD,"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0061|cit61","unstructured":"Luksenburg H Weir A Wager R EPO-INT-3: Safety Concerns Associated with Aranesp (darbepoetin alfa) Amgen, Inc. and Procrit (epoetin alfa) Ortho Biotech, L.P., for the Treatment of Anemia Associated with Cancer Chemotherapy Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Oncologic Drugs Advisory Committee Rockville (MD), USA, 2004"},{"issue":"9","key":"10.1002\/14651858.CD003407.pub5-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/bjc.2011.395","article-title":"Randomised, phase III trial of epoetin-B to treat chemotherapy-induced anaemia according to the EU regulation","volume":"105","author":"Fujisaka","year":"2011","journal-title":"British Journal of Cancer"},{"issue":"S8","key":"10.1002\/14651858.CD003407.pub5-BIB0063|cit63","first-page":"viii385","article-title":"A phase III, randomized, double-blind placebo-controlled study of epoetin beta in lung and gynecological cancer receiving platinum-based chemotherapy: Japan Erythropoietin Study Group","volume":"21","author":"Yoshizaki","year":"2010","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.critrevonc.2003.07.002","article-title":"Systemic chemotherapy in elderly patients with locally advanced and\/or inoperable squamous cell carcinoma of the head and neck: impact of anemia and role of recombinant human erythropoietin","volume":"48","author":"Gebbia","year":"2003","journal-title":"Critical Reviews in Oncology\/Hematology"},{"issue":"6","key":"10.1002\/14651858.CD003407.pub5-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1634\/theoncologist.2007-0241","article-title":"Treating anemia of cancer with every-4-week darbepoetin alfa: Final efficacy and safety results from a phase II, randomized, double-blind, placebo-controlled study","volume":"13","author":"Gordon","year":"2008","journal-title":"Oncologist"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0066|cit66","doi-asserted-by":"crossref","unstructured":"Gordon DH Nichols G Ben-Jacob A Lam H Lillie T Miller C Treating anemia of cancer with darbepoetin alfa administered every 4 weeks: Final results from a phase 2, randomized, double-Blind, placebo-controlled study in cancer patients not receiving chemotherapy and\/or radiotherapy Blood 2006 abstract 1304","DOI":"10.1182\/blood.V108.11.1304.1304"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0067|cit67","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0068|cit68","doi-asserted-by":"crossref","unstructured":"Goss G Feld R Bezjak A Perry G Melosky B Smith C Impact of maintaining Hb with epoetin alfa on time to progression (TTP), overall survival (OS), quality of life (QOL) and transfusion reduction in limited disease SCLC patients Lung cancer 2005 S53","DOI":"10.1016\/S0169-5002(05)80288-0"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0069|cit69","unstructured":"Luksenburg H Weir A Wager R Safety Concerns Associated with Aranesp (darbepoetin alfa) Amgen, Inc. and Procrit (epoetin alfa) Ortho Biotech, L.P., for the Treatment of Anemia Associated with Cancer Chemotherapy FDA Briefing Document May 4, 2004 Oncologic Drugs Advisory Committee"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0070|cit70","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0071|cit71","unstructured":"Johnson & Johnson Pharmaceutical Research & Development L.L.C Background information for Oncologic Drugs Advisory Committee Meeting, Safety of Erythropoietin Receptor Agonists (ERAs) in Patients with Cancer Johnson and Johnson briefing document for FDA\/ODAC hearing May 4, 2004; Gaithersburg, MD"},{"issue":"36","key":"10.1002\/14651858.CD003407.pub5-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"9377","DOI":"10.1200\/JCO.2005.01.8507","article-title":"Efficacy and safety analysis of epoetin alfa in patients with small-cell lung cancer: a randomized, double-blind, placebo-controlled trial","volume":"23","author":"Grote","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0073|cit73","unstructured":"Luksenburg H Weir A Wager R Safety Concerns Associated with Aranesp (darbepoetin alfa) Amgen, Inc. and Procrit(epoetin alfa) Ortho Biotech, L.P., for the Treatment of Anemia Associated with Cancer Chemotherapy FDA Briefing Document May 4, 2004 Oncologic Drugs Advisory Committee"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0074|cit74","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0075|cit75","unstructured":"Johnson & Johnson Pharmaceutical Research & Development L.L.C Background information for Oncologic Drugs Advisory Committee Meeting, Safety of Erythropoietin Receptor Agonists (ERAs) in Patients with Cancer Johnson and Johnson briefing document for FDA\/ODAC hearing May 4, 2004; Gaithersburg, MD,"},{"issue":"1","key":"10.1002\/14651858.CD003407.pub5-BIB0076|cit76","first-page":"13","article-title":"Recombinant human erythropoietin in patients of advanced Cancer treated \"by chemoradiotherapy\"","volume":"8","author":"Gupta","year":"2009","journal-title":"Landes Bioscience"},{"issue":"1","key":"10.1002\/14651858.CD003407.pub5-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1046\/j.1365-2141.2002.03774.x","article-title":"Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies","volume":"119","author":"Hedenus","year":"2002","journal-title":"British Journal of Haematology"},{"issue":"1","key":"10.1002\/14651858.CD003407.pub5-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1046\/j.1365-2141.2002.03774.x","article-title":"Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies","volume":"119","author":"Hedenus","year":"2002","journal-title":"British Journal of Haematology"},{"issue":"1","key":"10.1002\/14651858.CD003407.pub5-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1046\/j.1365-2141.2002.03774.x","article-title":"Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies","volume":"119","author":"Hedenus","year":"2002","journal-title":"British Journal of Haematology"},{"issue":"1","key":"10.1002\/14651858.CD003407.pub5-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1046\/j.1365-2141.2002.03774.x","article-title":"Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies","volume":"119","author":"Hedenus","year":"2002","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0081|cit81","unstructured":"Amgen Inc Aranesp\u00ae (darbepoetin alfa) safety Oncologic Drugs Advisory Committee, 4 May 2004"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1046\/j.1365-2141.2003.04448.x","article-title":"Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study","volume":"122","author":"Hedenus","year":"2003","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0083|cit83","unstructured":"Hedenus M Brandberg Y Molostova V Iosova G Abdulkadyrov K Messinger D Efficacy of epoetin beta in treating the anaemia of cancer in patients with haematological malignancies Proceedings of the 6th Congress of the European Haematology Association 2001 abstract 190"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0084|cit84","unstructured":"20000161 Continuing reassessment of the risks of erythropoiesis-stimulating agents (ESAs) administered for the treatment of anemia associated with cancer chemotherapy Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Oncologic Drugs Advisory Committee, Rockville (MD), USA, 2007"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0085|cit85","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD003407.pub5-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0167-8140(98)00115-7","article-title":"Erythropoietin for patients undergoing radiotherapy: a pilot study","volume":"50","author":"Henke","year":"1999","journal-title":"Radiotherapy and Oncology"},{"issue":"2","key":"10.1002\/14651858.CD003407.pub5-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0167-8140(98)00115-7","article-title":"Erythropoietin for patients undergoing radiotherapy: a pilot study","volume":"50","author":"Henke","year":"1999","journal-title":"Radiotherapy and Oncology"},{"issue":"2","key":"10.1002\/14651858.CD003407.pub5-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0167-8140(98)00115-7","article-title":"Erythropoietin for patients undergoing radiotherapy: a pilot study","volume":"50","author":"Henke","year":"1999","journal-title":"Radiotherapy and Oncology"},{"issue":"2","key":"10.1002\/14651858.CD003407.pub5-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0167-8140(98)00115-7","article-title":"Erythropoietin for patients undergoing radiotherapy: a pilot study","volume":"50","author":"Henke","year":"1999","journal-title":"Radiotherapy and Oncology"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(03)14567-9","article-title":"Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial","volume":"362","author":"Henke","year":"2003","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD003407.pub5-BIB0091|cit91","first-page":"292","article-title":"Erythropoietin in patients with head and neck carcinomas?","volume":"83","author":"Schipper","year":"2004","journal-title":"Laryngorhinootologie"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0092|cit92","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0093|cit93","unstructured":"Neorecormon (epoetin beta) Briefing package or the FDA Oncologic Advisory Committee Meeting, May 4, 2004"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1634\/theoncologist.1-3-140","article-title":"Recombinant Human Erythropoietin (rHuEPO) for the treatment of the anemia of cancer","volume":"1","author":"Abels","year":"1996","journal-title":"Oncologist"},{"issue":"2 (Suppl 3)","key":"10.1002\/14651858.CD003407.pub5-BIB0095|cit95","first-page":"21","article-title":"Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies","volume":"21","author":"Henry","year":"1994","journal-title":"Seminars in Oncology"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0096|cit96","first-page":"252","article-title":"Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy","volume":"1","author":"Henry","year":"1995","journal-title":"Cancer Journal from Scientific American"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0097|cit97","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0098|cit98","unstructured":"Johnson & Johnson Pharmaceutical Research & Development L.L.C Background information for Oncologic Drugs Advisory Committee Meeting, Safety of Erythropoietin Receptor Agonists (ERAs) in Patients with Cancer Johnson and Johnson briefing document for FDA\/ODAC hearing May 4, 2004; Gaithersburg, MD,"},{"issue":"9","key":"10.1002\/14651858.CD003407.pub5-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1185\/03007990903084164","article-title":"Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia","volume":"25","author":"Hernandez","year":"2009","journal-title":"Current Medical Research and Opinion"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0100|cit100","doi-asserted-by":"crossref","unstructured":"Taylor K Ganly P Charu V DiBenedetto J Kracht K Rossi G Randomized, double-blind, placebo-controlled study of darbepoetin alfa every 3 weeks for the treatment of chemotherapy-induced anemia Blood 2005 abstract 3556","DOI":"10.1182\/blood.V106.11.3556.3556"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0101|cit101","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"34","key":"10.1002\/14651858.CD003407.pub5-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"5751","DOI":"10.1200\/JCO.2009.22.3693","article-title":"Effect of Epoetin Alfa on Survival and Cancer Treatment-Related Anemia and Fatigue in Paatients Receiving Radical Radiotherapy With Curative Intent for Head and Neck Cancer","volume":"27","author":"Hoskin","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0103|cit103","unstructured":"Johnson & Johnson Pharmaceutical Research & Development L.L.C Background information for Oncologic Drugs Advisory Committee Meeting, Safety of Erythropoietin Receptor Agonists (ERAs) in Patients with Cancer Johnson and Johnson briefing document for FDA\/ODAC hearing May 4, 2004; Gaithersburg, MD,"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0104|cit104","unstructured":"Luksenburg H Weir A Wager R EPO-GBR-7: Safety Concerns Associated with Aranesp (darbepoetin alfa) Amgen Inc. and Procrit (epoetin alfa) Ortho Biotech L.P., for the Treatment of Anemia Associated with Cancer Chemotherapy Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Oncologic Drugs Advisory Committee, Rockville (MD), USA, 2004"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0105|cit105","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0106|cit106","unstructured":"Johnson & Johnson Pharmaceutical Research & Development L.L.C Background information for Oncologic Drugs Advisory Committee Meeting, Safety of Erythropoietin Receptor Agonists (ERAs) in Patients with Cancer Johnson and Johnson briefing document for FDA\/ODAC hearing May 4, 2004; Gaithersburg, MD,"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0107|cit107","first-page":"177","article-title":"A prospective randomised comparative-group evaluation of epoetin alfa for the treatment of anaemia in UK cancer patients receiving platinum-based chemotherapy","volume":"13 (Suppl 5)","author":"Huddart","year":"2002","journal-title":"Annals of Oncology"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0108|cit108","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD003407.pub5-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S0885-3924(03)00070-8","article-title":"Effect of recombinant human erythropoietin on quality of life in cancer patients receiving chemotherapy: results of a randomized, controlled trial","volume":"25","author":"Iconomou","year":"2003","journal-title":"Journal of Pain & Symptom Management"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1046\/j.1365-2141.1998.01085.x","article-title":"A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes","volume":"103","author":"Italian Cooperative Study Group For rHuEpo In Myelodysplastic Syndromes","year":"1998","journal-title":"British Journal of Haematology"},{"issue":"S8","key":"10.1002\/14651858.CD003407.pub5-BIB0111|cit111","first-page":"viii277","article-title":"Randomized, double-blind, placebo-controlled phase III study of weekly administration of darbepoetin alfa (DA) in anemic patients with lung or gynecologic cancer receiving platinum-containing chemotherapy","volume":"19","author":"Katakami","year":"2008","journal-title":"Annals of Oncology"},{"issue":"S1","key":"10.1002\/14651858.CD003407.pub5-BIB0112|cit112","first-page":"58","article-title":"Randomized, double-blind, placebo-controlled phase III study of weekly administration of darbepoetin alfa in anemic patients with lung or gynecologic cancer receiving platinum-containing chemotherapy","volume":"97","author":"Katsumata","year":"2009","journal-title":"Vox Sanguinis"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0113|cit113","doi-asserted-by":"crossref","unstructured":"Kotasek D Albertsson M Mackey J Darbepoetin Alfa 980291 Study Group Randomized, double-blind, placebo-controlled, dose-finding study of darbepoetin alfa administered once every 3 (Q3W) or 4 (Q4W) weeks in patients with solid tumors Proceedings of the American Society of Clinical Oncology 2002 356a","DOI":"10.1016\/S0959-8049(02)80431-2"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0114|cit114","unstructured":"Kotasek D Albertsson M Mackey J Steger G Rossi G O'Byne J Once per cycle dosing of darbepoetin alfa is feasible in anemic cancer patients receiving chemotherapy Annals of Oncology 2002 170"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0115|cit115","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0116|cit116","unstructured":"Kotasek D Berg R Poulsen E Colowick A Randomized, double-blind, placebo controlled, phase I\/II dose finding study of ARANESP (TM) administered once every three weeks in solid tumor patients Blood 2000 abstract 1268"},{"issue":"14","key":"10.1002\/14651858.CD003407.pub5-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/S0959-8049(03)00456-8","article-title":"Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study","volume":"39","author":"Kotasek","year":"2003","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0118|cit118","unstructured":"Kotasek D Berg R Poulsen E Colowick A Randomized, double-blind, placebo controlled, phase I\/II dose finding study of ARANESP (TM) administered once every three weeks in solid tumor patients Blood 2000 abstract 1268"},{"issue":"14","key":"10.1002\/14651858.CD003407.pub5-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/S0959-8049(03)00456-8","article-title":"Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study","volume":"39","author":"Kotasek","year":"2003","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0120|cit120","unstructured":"Kotasek D Berg R Poulsen E Colowick A Randomized, double-blind, placebo controlled, phase I\/II dose finding study of ARANESP (TM) administered once every three weeks in solid tumor patients Blood 2000 abstract 1268"},{"issue":"14","key":"10.1002\/14651858.CD003407.pub5-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/S0959-8049(03)00456-8","article-title":"Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study","volume":"39","author":"Kotasek","year":"2003","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0122|cit122","unstructured":"Kotasek D Berg R Poulsen E Colowick A Randomized, double-blind, placebo controlled, phase I\/II dose finding study of ARANESP (TM) administered once every three weeks in solid tumor patients Blood 2000 abstract 1268"},{"issue":"14","key":"10.1002\/14651858.CD003407.pub5-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/S0959-8049(03)00456-8","article-title":"Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study","volume":"39","author":"Kotasek","year":"2003","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0124|cit124","unstructured":"Kotasek D Berg R Poulsen E Colowick A Randomized, double-blind, placebo controlled, phase I\/II dose finding study of ARANESP (TM) administered once every three weeks in solid tumor patients Blood 2000 abstract 1268"},{"issue":"14","key":"10.1002\/14651858.CD003407.pub5-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/S0959-8049(03)00456-8","article-title":"Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study","volume":"39","author":"Kotasek","year":"2003","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0126|cit126","unstructured":"Kotasek D Berg R Poulsen E Colowick A Randomized, double-blind, placebo controlled, phase I\/II dose finding study of ARANESP (TM) administered once every three weeks in solid tumor patients Blood 2000 abstract 1268"},{"issue":"14","key":"10.1002\/14651858.CD003407.pub5-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/S0959-8049(03)00456-8","article-title":"Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study","volume":"39","author":"Kotasek","year":"2003","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0128|cit128","unstructured":"Kotasek D Berg R Poulsen E Colowick A Randomized, double-blind, placebo controlled, phase I\/II dose finding study of ARANESP (TM) administered once every three weeks in solid tumor patients Blood 2000 abstract 1268"},{"issue":"14","key":"10.1002\/14651858.CD003407.pub5-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/S0959-8049(03)00456-8","article-title":"Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study","volume":"39","author":"Kotasek","year":"2003","journal-title":"European Journal of Cancer"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0130|cit130","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.clon.2008.06.001","article-title":"Epoetin delta: efficacy in the treatment of anaemia in cancer patients receiving chemotherapy","volume":"20","author":"Krzakowski","year":"2008","journal-title":"Clinical Oncology"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.clon.2008.06.001","article-title":"Epoetin delta: efficacy in the treatment of anaemia in cancer patients receiving chemotherapy","volume":"20","author":"Krzakowski","year":"2008","journal-title":"Clinical Oncology"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.clon.2008.06.001","article-title":"Epoetin delta: efficacy in the treatment of anaemia in cancer patients receiving chemotherapy","volume":"20","author":"Krzakowski","year":"2008","journal-title":"Clinical Oncology"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s10147-001-8031-y","article-title":"Double-blind randomized control trial of the effect of recombinant human erythropoietin on chemotherapy-induced anemia in patients with non-small cell lung cancer","volume":"6","author":"Kunikane","year":"2001","journal-title":"International journal of clinical oncology"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s10147-001-8031-y","article-title":"Double-blind randomized control trial of the effect of recombinant human erythropoietin on chemotherapy-induced anemia in patients with non-small cell lung cancer","volume":"6","author":"Kunikane","year":"2001","journal-title":"International journal of clinical oncology"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s10147-001-8031-y","article-title":"Double-blind randomized control trial of the effect of recombinant human erythropoietin on chemotherapy-induced anemia in patients with non-small cell lung cancer","volume":"6","author":"Kunikane","year":"2001","journal-title":"International journal of clinical oncology"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1006\/gyno.1997.4675","article-title":"Erythropoietin treatment under polychemotherapy in patients with gynecologic malignancies: a prospective, randomized, double-blind placebo-controlled multicenter study","volume":"65","author":"Kurz","year":"1997","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0138|cit138","unstructured":"Johnson & Johnson Pharmaceutical Research & Development L.L.C Background information for Oncologic Drugs Advisory Committee Meeting, Safety of Erythropoietin Receptor Agonists (ERAs) in Patients with Cancer Johnson and Johnson briefing document for FDA\/ODAC hearing May 4, 2004; Gaithersburg, MD,"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0140|cit139","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(03)01163-X","article-title":"Breast cancer trial with erythropoietin terminated unexpectedly","volume":"4","author":"Leyland-Jones","year":"2003","journal-title":"Lancet Oncology"},{"issue":"25","key":"10.1002\/14651858.CD003407.pub5-BIB0139|cit140","doi-asserted-by":"crossref","first-page":"5865","DOI":"10.1200\/JCO.2005.06.150","article-title":"Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study","volume":"23","author":"Leyland-Jones","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0141|cit141","unstructured":"Luksenburg H Weir A Wager R Safety Concerns Associated with Aranesp (darbepoetin alfa) Amgen, Inc. and Procrit (epoetin alfa) Ortho Biotech, L.P., for the Treatment of Anemia Associated with Cancer Chemotherapy FDA Briefing Document May 4, 2004 Oncologic Drugs Advisory Committee"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0142|cit142","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3 Suppl 8","key":"10.1002\/14651858.CD003407.pub5-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1053\/sonc.2002.33534","article-title":"Age, anemia, and fatigue","volume":"29","author":"Aapro","year":"2002","journal-title":"Seminars in Oncology"},{"issue":"8","key":"10.1002\/14651858.CD003407.pub5-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1023\/A:1026116426494","article-title":"Evaluation of quality of life in a clinical trial with nonrandom dropout: the effect of epoetin alfa in anemic cancer patients","volume":"12","author":"Fairclough","year":"2003","journal-title":"Quality of Life Research"},{"issue":"12","key":"10.1002\/14651858.CD003407.pub5-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/sj.bjc.6600657","article-title":"Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy","volume":"87","author":"Fallowfield","year":"2002","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0150|cit146","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000061296","article-title":"Efficacy and quality of life outcomes of epoetin-alpha in a double-blind, placebo-controlled, multicentre study of cancer patients receiving non-platinum-containing chemotherapy","volume":"37","author":"Littlewood","year":"2002","journal-title":"Frontiers of Radiation Therapy and Oncology"},{"issue":"11","key":"10.1002\/14651858.CD003407.pub5-BIB0146|cit147","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1200\/JCO.2001.19.11.2865","article-title":"Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving non-platinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial","volume":"19","author":"Littlewood","year":"2001","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD003407.pub5-BIB0147|cit148","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(02)00827-6","article-title":"Erythropoietin improves quality of life","volume":"3","author":"Littlewood","year":"2002","journal-title":"Lancet Oncology"},{"issue":"4","key":"10.1002\/14651858.CD003407.pub5-BIB0148|cit149","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jpainsymman.2005.08.013","article-title":"Efficacy of darbepoetin alfa in alleviating fatigue and the effect of fatigue on quality of life in anemic patients with lymphoproliferative malignancies","volume":"31","author":"Littlewood","year":"2006","journal-title":"Journal of Pain & Symptom Management"},{"issue":"4","key":"10.1002\/14651858.CD003407.pub5-BIB0149|cit150","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/hon.722","article-title":"Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy","volume":"21","author":"Littlewood","year":"2003","journal-title":"Hematological Oncology"},{"issue":"16","key":"10.1002\/14651858.CD003407.pub5-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2165\/00019053-200321160-00002","article-title":"Cost-utility analysis of survival with epoetin-alfa versus placebo in stage IV breast cancer","volume":"21","author":"Martin","year":"2003","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0152|cit152","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0153|cit153","unstructured":"Johnson & Johnson Pharmaceutical Research & Development L.L.C Background information for Oncologic Drugs Advisory Committee Meeting, Safety of Erythropoietin Receptor Agonists (ERAs) in Patients with Cancer Johnson and Johnson briefing document for FDA\/ODAC hearing May 4, 2004; Gaithersburg, MD"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0154|cit154","unstructured":"Johnson & Johnson Pharmaceutical Research & Development L.L.C Background information for Oncologic Drugs Advisory Committee Meeting, Safety of Erythropoietin Receptor Agonists (ERAs) in Patients with Cancer Johnson and Johnson briefing document for FDA\/ODAC hearing May 4, 2004; Gaithersburg, MD,"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0155|cit155","unstructured":"Luksenburg H Weir A Wager R Safety Concerns Associated with Aranesp (darbepoetin alfa) Amgen, Inc. and Procrit (epoetin alfa) Ortho Biotech, L.P., for the Treatment of Anemia Associated with Cancer Chemotherapy FDA Briefing Document May 4, 2004 Oncologic Drugs Advisory Committee"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0156|cit156","doi-asserted-by":"crossref","unstructured":"Machtay M Pajak T Suntharalingam M Hershock D Stripp DC Cmelak A Definitive radiotherpay +\/- erythropoietin for squamous cell carcinoma of the head and neck: preliminary report of RTOG 99-03 International Journal of Radiation Oncology, Biology, Physics 2004 S132","DOI":"10.1016\/j.ijrobp.2004.06.031"},{"issue":"4","key":"10.1002\/14651858.CD003407.pub5-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.ijrobp.2007.04.063","article-title":"Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the Radiation Therapy Oncology Group (RTOG 99-03)","volume":"69","author":"Machtay","year":"2007","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0158|cit158","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0159|cit159","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD003407.pub5-BIB0160|cit160","first-page":"49","article-title":"Effects of epoetin alfa on anemia and patient-reported outcomes in patients with non-small cell lung cancer receiving chemotherapy: Results of a European, multicenter, randomized, controlled study","volume":"3","author":"Milroy","year":"2011","journal-title":"European Journal of Clinical and Medical Oncology"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0161|cit161","unstructured":"Multicenter, open label study of NeoRecormon treatment for anemia in adult patients with multiple myeloma, low grade non-Hodgkin's lymphoma or chronic lymphocytic leukemia who have a relatively erythropoietin deficiency and are receiving anti-tumor chemotherapy: ML17616 Shanghai, China:Shanghai Roche Pharmaceuticals Ltd; 2006"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0162|cit162","unstructured":"Multicenter, open label study of NeoRecormon prevention and treatment for anemia in adult patients withsolid tumors and treated with platinum-based chemotherapy prone to induce anemia. Study: ML17620 Shanghai, China:Shanghai Roche Pharmaceuticals Ltd; 2006"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0163|cit163","unstructured":"Moebus V Bastert G Kreienberg R Eidtmann H Cierna M Untch M Epoetin Alpha Prevents Anemia and Transfusions of RBCS in Patients Receiving Dose-Dense Sequential Chemotherapy Proceedings of the American Society of Clinical Oncology 2001 abstract 36"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0164|cit164","doi-asserted-by":"crossref","unstructured":"Moebus V Lueck H Thomssen C Harbeck N Nitz U Kreienberg R The impact of epoetin-alpha on anemia, red blood cell (RBC) transfusions, and survival in breast cancer patients (pts) treated with dose-dense sequential chemotherapy: Mature results of an AGO phase III study (ETC trial) Journal of Clinical Oncology 2007 569","DOI":"10.1200\/jco.2007.25.18_suppl.569"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0165|cit165","doi-asserted-by":"crossref","unstructured":"Moebus V Untch M du Bois A Lueck HJ Thomssen C Kuhn W Dose-dense sequential chemotherapy with epirubicin(E), paclitaxel (T) and cyclophosphamide (C) (ETC) is superior to conventional dosed chemotherapy in high-risk breast cancer patients (>= 4 +LN). First results of an AGO-trial Journal of Clinical Oncology 2004 abstract 513","DOI":"10.1200\/jco.2004.22.90140.513"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0166|cit166","doi-asserted-by":"crossref","unstructured":"Untch M Jackisch C Lenhard MS du Bois A Lueck HJ Thomssen C Epoetin-alpha reduces red blood cell transfusions (RBC) in high-risk breast cancer patients with adjuvant dose-dense, sequential chemotherapy with epirubicin (E), paclitaxel (T) and cyclophosphamide (C) (ETC) Journal of Clinical Oncology 2005 613","DOI":"10.1200\/jco.2005.23.16_suppl.613"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0167|cit167","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0168|cit168","unstructured":"Amgen Inc with contributions from Johnson & Johnson Pharmaceutical Research and Development L.L.C Safety of Erythropoiesis-Stimulating Agents (ESAs) in Oncology) Background information for Oncologic Drugs Advisory Committee 10 May 2007"},{"issue":"5","key":"10.1002\/14651858.CD003407.pub5-BIB0169|cit169","first-page":"3495","article-title":"Evaluation of epoetin supplemented with oral iron in patients with solid malignancies and chronic anemia not receiving anticancer treatment","volume":"25","author":"Mystakidou","year":"2005","journal-title":"Anticancer Research"},{"issue":"6","key":"10.1002\/14651858.CD003407.pub5-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3816\/CBC.2005.n.002","article-title":"Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy","volume":"5","author":"O'Shaughnessy","year":"2005","journal-title":"Clinical Breast Cancer"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0171|cit171","doi-asserted-by":"crossref","unstructured":"O'Shaugnessy J Vukelja S Savin M Holmes FA Jones M Royall D Effects of epoetin alfa (Procrit) on cognitive function, mood, asthenia, and quality of life in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy: a double-blind, randomized, placebo-controlled trial Proceedings of the American Society of Clinical Oncology 2002 abstract 1449","DOI":"10.3816\/CBC.2002.s.022"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0172|cit172","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0173|cit173","unstructured":"Anonymous A placebo-controlled study on the effect of epoetin alfa in patients with malignancy receiving chemotherapy. Raritan (NJ): Johnson and Johhnson Pharmaceutical Research and Development Available at www.clinicaltrials.gov\/ct2\/show\/NCT00270166 2005."},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0174|cit174","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0176|cit175","unstructured":"Neorecormon (epoetin beta) Briefing package or the FDA Oncologic Advisory Committee Meeting, May 4, 2004"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0175|cit176","unstructured":"Ehmer B Schrenk U Franks W Quardor O Messinger D Clinical efficacy of epoetin beta (EPO) in the correction of chemotherapy (CT) induced anemia in patients with solid cancer: a randomized controlled clinical trial Annals of Oncololgy 1996 A2960"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0177|cit177","unstructured":"Oberhoff C Krumeich B Winkler UH Hoffmann O Schindler AE Recombinant human erythropoietin (epoetin beta) in the treatment of chemotherapy - associated anaemia: effects on blood coagulation and fibrinolysis in patients with gynecological malignancies Annals of Hematology 2000 B16"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1023\/A:1008296622469","article-title":"Recombinant human erythropoietin in the treatment of chemotherapy- induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study","volume":"9","author":"Oberhoff","year":"1998","journal-title":"Annals of Oncology"},{"issue":"4","key":"10.1002\/14651858.CD003407.pub5-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1055\/s-2005-858478","article-title":"Prevention and therapy of anemia in tumor patients with Epoetin beta (NeoRecormon)","volume":"26","author":"Oberhoff","year":"2005","journal-title":"Tumor Diagnostik und Therapie"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0180|cit180","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0181|cit181","unstructured":"Neorecormon (epoetin beta) Briefing package or the FDA Oncologic Advisory Committee Meeting, May 4, 2004"},{"issue":"7","key":"10.1002\/14651858.CD003407.pub5-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1182\/blood.V87.7.2675.bloodjournal8772675","article-title":"Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma--a randomized multicenter study","volume":"87","author":"Osterborg","year":"1996","journal-title":"Blood"},{"issue":"7","key":"10.1002\/14651858.CD003407.pub5-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1182\/blood.V87.7.2675.bloodjournal8772675","article-title":"Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma--a randomized multicenter study","volume":"87","author":"Osterborg","year":"1996","journal-title":"Blood"},{"issue":"7","key":"10.1002\/14651858.CD003407.pub5-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1182\/blood.V87.7.2675.bloodjournal8772675","article-title":"Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma--a randomized multicenter study","volume":"87","author":"Osterborg","year":"1996","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0185|cit185","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0186|cit186","unstructured":"Neorecormon (epoetin beta) Briefing package or the FDA Oncologic Advisory Committee Meeting, May 4, 2004"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1365-2141.2005.05440.x","article-title":"Impact of epoetin-\u00df on survival of patients with lymphoproliferative malignancies: long-term follow up of a large randomized study","volume":"129","author":"Osterborg","year":"2005","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1365-2141.2005.05440.x","article-title":"Impact of epoetin-\u00df on survival of patients with lymphoproliferative malignanices: long-term follow up of a large randomized study","volume":"129","author":"Osterborg","year":"2005","journal-title":"British Journal of Haematology"},{"issue":"10","key":"10.1002\/14651858.CD003407.pub5-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1200\/JCO.2002.08.131","article-title":"Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies","volume":"20","author":"Osterborg","year":"2002","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0190|cit190","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0191|cit191","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3, Art. No.: CD","key":"10.1002\/14651858.CD003407.pub5-BIB0192|cit192","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006158.pub2","article-title":"Erythropoietin as an adjuvant treatment with (chemo) radiation therapy for head and neck cancer","author":"Lambin","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0195|cit193","unstructured":"Overgaard J Interim Analysis of DAHANCA 10 http:\/\/www.dahanca.dk\/get_media_file.php?mediaid=125 [accessed April 1, 2009]"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0193|cit194","first-page":"6007","article-title":"Randomized study of darbepoetin alfa as modifier of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC): Final outcome of the DAHANCA 10 trial","volume":"27","author":"Overgaard","year":"2009","journal-title":"ASCO Meeting Abstracts"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0194|cit195","doi-asserted-by":"crossref","unstructured":"Overgaard J Hoff C Sand Hansen H Specht L Overgaard M Grau C Randomized study of the importance of Novel Erythropoiesis Stimulating Protein (Aranesp\u00ae) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC) - the Danish Head and Neck Cancer Group DAHANCA 10 randomized trial European Journal of Cancer Supplements 2007 abstract 6LB","DOI":"10.1016\/S1359-6349(07)70099-X"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0196|cit196","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0197|cit197","unstructured":"Johnson & Johnson Pharmaceutical Research & Development L.L.C Background information for Oncologic Drugs Advisory Committee Meeting, Safety of Erythropoietin Receptor Agonists (ERAs) in Patients with Cancer Johnson and Johnson briefing document for FDA\/ODAC hearing May 4, 2004; Gaithersburg, MD,"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0198|cit198","unstructured":"Luksenburg H Weir A Wager R P-174 in: Safety Concerns Associated with Aranesp (darbepoetin alfa) Amgen, Inc. and Procrit (epoetin alfa) Ortho Biotech, L.P., for the Treatment of Anemia Associated with Cancer Chemotherapy Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Oncologic Drugs Advisory Committee Rockville (MD), USA, 2004"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/j.1365-2141.1995.tb08374.x","article-title":"Effective treatment of disease-related anaemia in B-chronic lymphocytic leukaemia patients with recombinant human erythropoietin","volume":"89","author":"Pangalis","year":"1995","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0200|cit200","unstructured":"Amgen Aranesp(R) ``145 Study'' Shows No Difference in Survival in Patients with Small-Cell Lung Cancer Amgen Thousand Oaks, CA, 2007"},{"issue":"14","key":"10.1002\/14651858.CD003407.pub5-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1200\/JCO.2007.15.0748","article-title":"Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide","volume":"26","author":"Pirker","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0202|cit202","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0203|cit203","unstructured":"Pronzato P Cortesi E Van der Rijt C Moreno-Nogueria A Raimundo D Ostler P Early intervention with epoetin alfa in breast cancer (BC) patients (pts) undergoing chemotherapy (CT): results of a randomized, multicenter, phase IIIb study (EPO-INT-47 Study Group) Annals of Oncology 2002 168"},{"issue":"9","key":"10.1002\/14651858.CD003407.pub5-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1634\/theoncologist.2009-0279","article-title":"Epoetin alfa improves anemia and anemia-related, patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy: results of a European, multicenter, randomized, controlled trial","volume":"15","author":"Pronzato","year":"2010","journal-title":"Oncologist"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0205|cit205","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10 (Suppl 1)","key":"10.1002\/14651858.CD003407.pub5-BIB0206|cit206","first-page":"347a","article-title":"The role of recombinant human erythropoietin (EPO) in reducing red blood cell transfusions and maintaining quality of life (QOL) in patients with lymphoma and solid tumors receiving cytotoxic chemotherapy. Results of a randomized, double-blind, placebo-controlled clinical trial","volume":"88","author":"Quirt","year":"1996","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0207|cit207","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0208|cit208","doi-asserted-by":"crossref","unstructured":"Ray-Coquard I Dussart S Goillot C Mayeur D Debourdeau P Ghesquieres H A risk model for severe anemia to select cancer patients for primary prophylaxis with epoetin {alpha}: a prospective randomized controlled trial of the ELYPSE study group Annals of Oncology 2009","DOI":"10.1093\/annonc\/mdn750"},{"issue":"Suppl 9","key":"10.1002\/14651858.CD003407.pub5-BIB0209|cit209","first-page":"ix294","article-title":"ELYPSE 4: A prospective randomized trial comparing Epo A in primary prophylaxis of severe anemia requiring red cells transfusion in high risk patients","volume":"17","author":"Ray-Coquard","year":"2006","journal-title":"Annals of Oncology"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0210|cit210","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0211|cit211","doi-asserted-by":"crossref","unstructured":"Razzouk BI Hockenberry M Hinds PS Rackoff W Hord JD A double-blind, placebo-controlled study of once-weekly epoetin alfa in children with cancer undergoing myelosuppressive chemotherapy Journal of Clinical Oncology 2004 Abstract #8527","DOI":"10.1200\/jco.2004.22.90140.8527"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0212|cit212","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6 Suppl 4","key":"10.1002\/14651858.CD003407.pub5-BIB0213|cit213","first-page":"10","article-title":"Hemoglobin response and improvements in quality of life in anemic children with cancer receiving myelosuppressive chemotherapy","volume":"3","author":"Hinds","year":"2005","journal-title":"Journal of Supportive Oncology"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0214|cit214","doi-asserted-by":"crossref","unstructured":"Razzouk BI Hockenberry M Hinds PS Feusner J Rackoff W Hord JD Influence of hemoglobin response to epoetin alfa on quality-of-life in anemic children with cancer receiving myelosuppressive chemotherapy Blood 2004 abstract 221","DOI":"10.1182\/blood.V104.11.2218.2218"},{"issue":"22","key":"10.1002\/14651858.CD003407.pub5-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1200\/JCO.2005.03.4371","article-title":"Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapy","volume":"24","author":"Razzouk","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"10 (Suppl 1)","key":"10.1002\/14651858.CD003407.pub5-BIB0216|cit216","first-page":"526a","article-title":"Clinical and health status assessments in anemic chronic lymphocytic leukemia (CLL) patients treated with epoetin alfa (EPO)","volume":"84","author":"Rose","year":"1994","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0217|cit217","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0218|cit218","unstructured":"Johnson & Johnson Pharmaceutical Research & Development L.L.C Background information for Oncologic Drugs Advisory Committee Meeting, Safety of Erythropoietin Receptor Agonists (ERAs) in Patients with Cancer Johnson and Johnson briefing document for FDA\/ODAC hearing May 4, 2004; Gaithersburg, MD,"},{"issue":"5","key":"10.1002\/14651858.CD003407.pub5-BIB0219|cit219","first-page":"1689","article-title":"Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer","volume":"9","author":"Rosen","year":"2003","journal-title":"Clinical Cancer Research"},{"issue":"2","key":"10.1002\/14651858.CD003407.pub5-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jpainsymman.2003.06.010","article-title":"The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events","volume":"27","author":"Rosenzweig","year":"2004","journal-title":"Journal of Pain & Symptom Management"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0221|cit221","doi-asserted-by":"crossref","unstructured":"Savonije J Van Groeningen C Van Bochove A Pinedo H Giaccone G Early intervention with epoetin-alfa during platinum-based chemotherapy Journal of Clinical Oncology 2004 #8111","DOI":"10.1200\/jco.2004.22.90140.8111"},{"issue":"11","key":"10.1002\/14651858.CD003407.pub5-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/j.ejca.2005.03.024","article-title":"Effects of early intervention with epoetin alfa on transfusion requirement, hemoglobin level and survival during platinum-based chemotherapy: Results of a multicenter randomised controlled trial","volume":"41","author":"Savonije","year":"2005","journal-title":"European Journal of Cancer"},{"issue":"2","key":"10.1002\/14651858.CD003407.pub5-BIB0223|cit223","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1634\/theoncologist.11-2-197","article-title":"Early Intervention with epoetin alfa during platinum-based chemotherapy: an analysis of quality-of-life results of a multicenter, randomized, controlled trial compared with population normative data","volume":"11","author":"Savonije","year":"2006","journal-title":"The oncologist"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0224|cit224","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0225|cit225","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/BF01696618","article-title":"Long-term therapy with recombinant human erythropoietin (rHu-EPO) in progressing multiple myeloma","volume":"70","author":"Silvestris","year":"1995","journal-title":"Annals of Hematology"},{"issue":"12","key":"10.1002\/14651858.CD003407.pub5-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1038\/sj.bjc.6600994","article-title":"A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer","volume":"88","author":"Smith","year":"2003","journal-title":"British Journal of Cancer"},{"issue":"12","key":"10.1002\/14651858.CD003407.pub5-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1038\/sj.bjc.6600994","article-title":"A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer","volume":"88","author":"Smith","year":"2003","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0228|cit228","unstructured":"Amgen Inc with contributions from Johnson & Johnson Pharmaceutical Research and Development L.L.C Safety of Erythropoiesis-Stimulating Agents (ESAs) in Oncology) Background information for Oncologic Drugs Advisory Committee 10 May 2007"},{"issue":"12","key":"10.1002\/14651858.CD003407.pub5-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1038\/sj.bjc.6600994","article-title":"A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer","volume":"88","author":"Smith","year":"2003","journal-title":"British Journal of Cancer"},{"issue":"12","key":"10.1002\/14651858.CD003407.pub5-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1038\/sj.bjc.6600994","article-title":"A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer","volume":"88","author":"Smith","year":"2003","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0231|cit231","unstructured":"20010103 Continuing reassessment of the risks of erythropoiesis-stimulating agents (ESAs) administered for the treatment of anemia associated with cancer chemotherapy Department of Health and Human Services, Food and Drugs Administration, Center for Drug Evaluation and Research, Oncologic Drugs Advisory Committee, Rockville (MD), USA, 2007"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0232|cit232","unstructured":"Glaspy J Smith RE Aapro M Ludwig H Pinter T Smakal M Results from a phase 3 randomized, double blind, placebo controlled study of darbepoetin alfa for the treatment of anemia in cancer patients not receiving chemotherapy or radiotherapy Haematologica 2007 136"},{"issue":"7","key":"10.1002\/14651858.CD003407.pub5-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1200\/JCO.2007.14.2885","article-title":"Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study","volume":"26","author":"Smith","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0234|cit234","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0235|cit235","doi-asserted-by":"crossref","unstructured":"Strauss H Haendgen G Dunst.J Koelbl H Effects of anaemia correction with epoetin beta in patients with advanced cervical cancer Proceedings of the American Society of Clinical Oncology 2003 abstract 5121","DOI":"10.1200\/jco.2005.23.16_suppl.5121"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD003407.pub5-BIB0236|cit236","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1525-1438.2007.01032.x","article-title":"Effects of anemia correction with epoetin beta in patients receiving radiochemotherapy for advanced cervical cancer","volume":"18","author":"Strauss","year":"2008","journal-title":"International Journal of Gynecological Cancer"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0237|cit237","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"S8","key":"10.1002\/14651858.CD003407.pub5-BIB0238|cit238","first-page":"viii277","article-title":"Randomized, placebo-controlled phase II study of darbepoetin alfa (DA) administered every three weeks (Q3W) in patients with chemotherapy-induced anemia (CIA)","volume":"19","author":"Suzuki","year":"2008","journal-title":"Annals of Oncology"},{"issue":"S8","key":"10.1002\/14651858.CD003407.pub5-BIB0239|cit239","first-page":"viii277","article-title":"Randomized, placebo-controlled phase II study of darbepoetin alfa (DA) administered every three weeks (Q3W) in patients with chemotherapy-induced anemia (CIA)","volume":"19","author":"Suzuki","year":"2008","journal-title":"Annals of Oncology"},{"issue":"S8","key":"10.1002\/14651858.CD003407.pub5-BIB0240|cit240","first-page":"viii277","article-title":"Randomized, placebo-controlled phase II study of darbepoetin alfa (DA) administered every three weeks (Q3W) in patients with chemotherapy-induced anemia (CIA)","volume":"19","author":"Suzuki","year":"2008","journal-title":"Annals of Oncology"},{"issue":"11","key":"10.1002\/14651858.CD003407.pub5-BIB0241|cit241","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1038\/bjc.1998.331","article-title":"Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: final report of a randomized, open- labelled, phase II trial","volume":"77","author":"Sweeney","year":"1998","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/0360-3016(93)90299-B","article-title":"Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: preliminary results of a randomized, open-labeled, phase II trial","volume":"26","author":"Vijayakumar","year":"1993","journal-title":"International Journal of Radiation Oncology, Biology and Physics"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0243|cit243","unstructured":"Neorecormon (epoetin beta) Briefing package or the FDA Oncologic Advisory Committee Meeting, May 4, 2004"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0244|cit244","doi-asserted-by":"crossref","unstructured":"Reed N Rhan S Hayward C Burger H Ten Bokkel Huinink W Impact of epoetin beta on the survival of anemic patients with ovarian cancer receiving platinum-based chemotherapy Proceedings of the American Society of Clinical Oncology 2003 abstract 5102","DOI":"10.1200\/jco.2005.23.16_suppl.5102"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0245|cit245","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/BF02821936","article-title":"Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy","volume":"15","author":"Bokkel Huinink","year":"1998","journal-title":"Medical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0246|cit246","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/BF02821936","article-title":"Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy","volume":"15","author":"Bokkel Huinink","year":"1998","journal-title":"Medical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0247|cit247","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/BF02821936","article-title":"Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy","volume":"15","author":"Bokkel Huinink","year":"1998","journal-title":"Medical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0248|cit248","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD003407.pub5-BIB0249|cit249","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1200\/JCO.1995.13.7.1623","article-title":"Clinical and and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancer","volume":"13","author":"Campos","year":"1995","journal-title":"Journal of Clinical Oncology"},{"issue":"3-4","key":"10.1002\/14651858.CD003407.pub5-BIB0250|cit250","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/sj.bjc.6690369","article-title":"Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer","volume":"80","author":"Thatcher","year":"1999","journal-title":"British Journal of Cancer"},{"issue":"3-4","key":"10.1002\/14651858.CD003407.pub5-BIB0251|cit251","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/sj.bjc.6690369","article-title":"Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer","volume":"80","author":"Thatcher","year":"1999","journal-title":"British Journal of Cancer"},{"issue":"3-4","key":"10.1002\/14651858.CD003407.pub5-BIB0252|cit252","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/sj.bjc.6690369","article-title":"Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer","volume":"80","author":"Thatcher","year":"1999","journal-title":"British Journal of Cancer"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0253|cit253","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0254|cit254","unstructured":"Thomas H McAdam KF Thomas RJ Joffe JK Sugden EM Awwad ST Early intervention with epoetin alfa for treatment of anaemia and improvement of quality of life in cancer patients undergoing myelotoxic chemotherapy Annals of Oncology 2002 177, #653P"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0255|cit255","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0256|cit256","unstructured":"Johnson & Johnson Pharmaceutical Research & Development L.L.C Background information for Oncologic Drugs Advisory Committee Meeting, Safety of Erythropoietin Receptor Agonists (ERAs) in Patients with Cancer Johnson and Johnson briefing document for FDA\/ODAC hearing May 4, 2004; Gaithersburg, MD,"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0257|cit257","unstructured":"Luksenburg H Weir A Wager R GOG-191: Safety concerns associated with Aranesp (darbepoetin alfa) Amgen Inc. and Procrit (epoetin alfa) Ortho Biotech L.P., for the treatment of Anemia Associated with Cancer Chemotherapy Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Oncologic Drugs Advisory Committee, Rockville (MD), USA, 2004"},{"issue":"2","key":"10.1002\/14651858.CD003407.pub5-BIB0258|cit258","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ygyno.2007.10.011","article-title":"Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0\u00a0g\/dL with erythropoietin vs above 10.0\u00a0g\/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer","volume":"108","author":"Thomas","year":"2008","journal-title":"Gynecologic Oncology"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0259|cit259","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0260|cit260","unstructured":"Johnson & Johnson Pharmaceutical Research & Development L.L.C Background information for Oncologic Drugs Advisory Committee Meeting, Safety of Erythropoietin Receptor Agonists (ERAs) in Patients with Cancer Johnson and Johnson briefing document for FDA\/ODAC hearing May 4, 2004; Gaithersburg, MD,"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0261|cit261","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1182\/blood.V95.4.1175.004k51_1175_1179","article-title":"Effect of recombinant human erythropoietin combined with granulocyte\/macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome","volume":"95","author":"Thompson","year":"2000","journal-title":"Blood"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0262|cit262","first-page":"Abstract 1558","article-title":"Erythropoietin decreases transfusion requirements during radiochemotherapy","volume":"19","author":"Throuvalas","year":"2000","journal-title":"Proceedings of the American Society of Clinical Oncologists"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0263|cit263","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1753-5174.2010.00030.x","article-title":"Epoetin theat in anaemic cancer patients receiving platinum-based chemotherapy: a randomised controlled trial.","volume":"3","author":"Tjulandin","year":"2010","journal-title":"Archives of Drug Information"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0264|cit264","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1753-5174.2010.00030.x","article-title":"Epoetin theat in anaemic cancer patients receiving platinum-based chemotherapy: a randomised controlled trial.","volume":"3","author":"Tjulandin","year":"2010","journal-title":"Archives of Drug Information"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0265|cit265","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1753-5174.2010.00030.x","article-title":"Epoetin theat in anaemic cancer patients receiving platinum-based chemotherapy: a randomised controlled trial.","volume":"3","author":"Tjulandin","year":"2010","journal-title":"Archives of Drug Information"},{"issue":"Supplement 4","key":"10.1002\/14651858.CD003407.pub5-BIB0266|cit266","first-page":"88, Abstract V3","article-title":"Epoetin theta shows efficacy and safety in a placebo controlled, randomized phase III study in cancer patients receiving non-platinum chemotherapy","volume":"32","author":"Buchner","year":"2009","journal-title":"Onkologie"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0267|cit267","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1753-5174.2011.00035.x","article-title":"Epoetin theta with a new dosing schedule in anaemic cancer patients receiving nonplatinum-based chemotherapy: a randomised controlled trial","volume":"4","author":"Tjulandin","year":"2011","journal-title":"Archives of Drug Information"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0268|cit268","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/jjco\/hyn151","article-title":"Weekly administration of epoetin beta for chemotherapy-induced anemia in cancer patients: results of a multicenter, Phase III, randomized, double-blind, placebo-controlled study","volume":"39","author":"Tsuboi","year":"2009","journal-title":"Japanese Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0269|cit269","unstructured":"Watanabe M Ezaki K Tobinai K Tsuboi M Ohashi Y Hirashima K A multicenter phase III randomized, double-blind placebo-controlled study of Epoetin beta administered once-weekly for chemotherapy induced anemia (CIA) in cancer patients: Japan Erythropoietin Study Group Annals of Oncology 2006 294"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0270|cit270","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD003407.pub5-BIB0271|cit271","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1093\/annonc\/mdq709","article-title":"PREPARE trial: A randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin\/cyclophosphamide followed by paclitaxel (plus or minus) darbepoetin alfa in primary breast cancer-results at the time of surgery","volume":"22","author":"Untch","year":"2011","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0272|cit272","doi-asserted-by":"crossref","unstructured":"Untch M Fascing PA Bauernfeind I Conrad U Camara O Fett W PREPARE trial. A randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF with a standard dosed epirubicin\/cyclophosphamide followed by paclitaxel +\/- darbepoetin alfa in primary breast cancer: A preplanned interim analysis of efficacy at surgery Journal of Clinical Oncology 2008 abstract 517","DOI":"10.1200\/jco.2008.26.15_suppl.517"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0273|cit273","doi-asserted-by":"crossref","unstructured":"Untch M Fascing PA Bauernfeind I Conrad U Camara O Fett W PREPARE trial. A randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF with a standard dosed epirubicin\/cyclophosphamide followed by paclitaxel +\/- darbepoetin alfa in primary breast cancer: A preplanned interim analysis of efficacy at surgery Journal of Clinical Oncology 2008 abstract 517","DOI":"10.1200\/jco.2008.26.15_suppl.517"},{"issue":"9","key":"10.1002\/14651858.CD003407.pub5-BIB0274|cit274","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1093\/annonc\/mdq713","article-title":"PREPARE trial: A randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin\/cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer-outcome on prognosis","volume":"22","author":"Untch","year":"2011","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0275|cit275","unstructured":"Luksenburg H Weir A Wager R Safety Concerns Associated with Aranesp(darbepoetin alfa) Amgen, Inc. and Procrit(epoetin alfa) Ortho Biotech, L.P., for the Treatment of Anemia Associated with Cancer Chemotherapy FDA Briefing Document May 4, 2004 Oncologic Drugs Advisory Committee"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0276|cit276","unstructured":"Amgen Inc Aranesp\u00ae (darbepoetin alfa) safety Oncologic Drugs Advisory Committee, 4 May 2004"},{"issue":"9 Suppl 10","key":"10.1002\/14651858.CD003407.pub5-BIB0277|cit277","first-page":"117","article-title":"Psychological outcomes associated with anemia-related fatigue in cancer patients","volume":"16","author":"Kallich","year":"2002","journal-title":"Oncology (Huntingt)"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0278|cit278","doi-asserted-by":"crossref","unstructured":"Pirker R Vansteenkiste J Gateley J Yates P Colowick A Musil J A phase 3, double-blind, placebo-controlled, randomized study of novel erythropoiesis stimulating protein (NESP) in patients undergoing platinum treatment for lung cancer Proceedings of the American Society of Clinical Oncology 2001 abstract 1572","DOI":"10.1016\/S0959-8049(01)81473-8"},{"issue":"1","key":"10.1002\/14651858.CD003407.pub5-BIB0279|cit279","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/cncr.11463","article-title":"The relationship between psychologic distress and cancer-related fatigue","volume":"98","author":"Tchekmedyian","year":"2003","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0280|cit280","unstructured":"Tchekmedyian S Glaspy J Colowick A Tomita D Rossi G Effect of darbepoetin alfa and recombinant human erythropoietin (rHuEPO) on early hemoglobin (Hb) changes in anemic cancer patients (pts) Annals of Oncology 2002 184"},{"issue":"16","key":"10.1002\/14651858.CD003407.pub5-BIB0281|cit281","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1093\/jnci\/94.16.1211","article-title":"Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy.[see comment]","volume":"94","author":"Vansteenkiste","year":"2002","journal-title":"Journal of the National Cancer Institute"},{"issue":"10 Suppl 11","key":"10.1002\/14651858.CD003407.pub5-BIB0282|cit282","first-page":"45","article-title":"Darbepoetin alfa: impact on treatment for chemotherapy-induced anemia and considerations in special populations","volume":"16","author":"Vansteenkiste","year":"2002","journal-title":"Oncology (Huntingt)"},{"issue":"4","key":"10.1002\/14651858.CD003407.pub5-BIB0283|cit283","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00520-003-0583-0","article-title":"Darbepoetin alfa in lung cancer patients on chemotherapy: a retrospective comparison of outcomes in patients with mild versus moderate-to-severe anaemia at baseline","volume":"12","author":"Vansteenkiste","year":"2004","journal-title":"Supportive Care in Cancer"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0284|cit284","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0285|cit285","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1159\/000204782","article-title":"Recombinant human erythropoietin in patients with ovarian carcinoma and anaemia secondary to cisplatin and carboplatin chemotherapy: preliminary results","volume":"87 (Suppl 1)","author":"James","year":"1992","journal-title":"Acta Haematologica"},{"issue":"4","key":"10.1002\/14651858.CD003407.pub5-BIB0286|cit286","first-page":"261","article-title":"Recombinant human erythropoietin and platinum-based chemotherapy in advanced ovarian cancer","volume":"1","author":"Welch","year":"1995","journal-title":"Cancer Journal of the Scientific American"},{"issue":"7","key":"10.1002\/14651858.CD003407.pub5-BIB0287|cit287","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/sj.bjc.6603004","article-title":"Epoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre, randomised trial","volume":"94","author":"Wilkinson","year":"2006","journal-title":"British Journal of Cancer"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0288|cit288","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD003407.pub5-BIB0289|cit289","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1200\/JCO.2008.20.4966","article-title":"Randomized, double-blind, placebo-controlled trial of epoetin alfa in men with castration-resistant prostate cancer and anemia","volume":"27","author":"Winquist","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0290|cit290","doi-asserted-by":"crossref","unstructured":"Dicato M Vercammen E Liu KL Xiu LX Bowers P Relationship of body weight to efficacy of a fixed-dose regimen of epoetin alfa vs placebo in anemic cancer patients Haematologica 2005 abstract 0077","DOI":"10.1200\/jco.2005.23.16_suppl.8192"},{"issue":"12","key":"10.1002\/14651858.CD003407.pub5-BIB0291|cit291","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1200\/JCO.2004.10.020","article-title":"Phase III, randomized, double-blind study of epoetin alfa versus placebo in anemic patients with cancer undergoing chemotherapy","volume":"23","author":"Witzig","year":"2005","journal-title":"Journal of Clinical Oncoogy"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0292|cit292","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0293|cit293","unstructured":"Johnson & Johnson Pharmaceutical Research & Development L.L.C Background information for Oncologic Drugs Advisory Committee Meeting, Safety of Erythropoietin Receptor Agonists (ERAs) in Patients with Cancer Johnson and Johnson briefing document for FDA\/ODAC hearing May 4, 2004; Gaithersburg, MD,"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0294|cit294","unstructured":"Luksenburg H Weir A Wager R EPO-CAN-20: Safety Concerns Associated with Aranesp (darbepoetin alfa) Amgen Inc and Procrit (epoetin alfa) Ortho Biotech L.P. for the Treatment of Anemia Associated with Cancer Chemotherapy Oncologic Drugs Advisory Committee, Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Rockville (MD), USA, 2004"},{"issue":"9","key":"10.1002\/14651858.CD003407.pub5-BIB0295|cit295","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1200\/JCO.2006.07.1514","article-title":"Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia","volume":"25","author":"Wright","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0296|cit296","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD003407.pub5-BIB0297|cit297","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1046\/j.1537-2995.1996.36296181929.x","article-title":"Prevention of chemotherapy-induced anemia by the use of erythropoietin in patients with primary malignant bone tumors (a double-blind, randomized, phase III study)","volume":"36","author":"Wurnig","year":"1996","journal-title":"Transfusion"},{"issue":"11","key":"10.1002\/14651858.CD003407.pub5-BIB0298|cit298","first-page":"12","article-title":"Review, Approval, and Marketingof Biosimilars in the United StatesPart 1: Safety and Regulatory Issues","volume":"8","author":"Aagaard","year":"2010","journal-title":"BioProcess International"},{"issue":"12","key":"10.1002\/14651858.CD003407.pub5-BIB0299|cit299","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1038\/sj.bjc.6605255","article-title":"Epoetin-beta treatment in patients with cancer chemotherapy-induced anaemia: the impact of initial haemoglobin and target haemoglobin levels on survival, tumour progression and thromboembolic events","volume":"101","author":"Aapro","year":"2009","journal-title":"British Journal of Cancer"},{"issue":"6","key":"10.1002\/14651858.CD003407.pub5-BIB0300|cit300","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1080\/10245330701521572","article-title":"Once weekly recombinant human erythropoietin treatment for cancer-induced anemia in children with acute lymphoblastic leukemia receiving maintenance chemotherapy: A randomized case-controlled study","volume":"12","author":"Abdelrazik","year":"2007","journal-title":"Hematology"},{"issue":"1","key":"10.1002\/14651858.CD003407.pub5-BIB0301|cit301","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S1548-5315(12)70002-5","article-title":"Eribulin in patients with metastatic breast cancer previously treated with an anthracycline and a taxane","volume":"8","author":"Abraham","year":"2011","journal-title":"Community Oncology"},{"issue":"5","key":"10.1002\/14651858.CD003407.pub5-BIB0302|cit302","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/j.1537-2995.2009.02165.x","article-title":"Erythropoietic-stimulating agents: the cancer progression controversy and collateral damage to the blood supply.[comment]","volume":"49","author":"Adamson","year":"2009","journal-title":"Transfusion"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0303|cit303","first-page":"abstract 832P","article-title":"A randomized comparison of rHuEPO with darbepoetin for cancer related anemia","volume":"15 Suppl 3","author":"Alexopoulos","year":"2004","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0304|cit304","unstructured":"Alexopoulos CG KA A randomized comparison of rHuEPO with darbepoetin for cancer related anemia Annals of Oncology 2004"},{"issue":"5","key":"10.1002\/14651858.CD003407.pub5-BIB0305|cit305","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1200\/JOP.0753501","article-title":"Erythropoiesis-stimulating agents: Continued challenges","volume":"3","author":"Anonymous","year":"2007","journal-title":"Journal of Oncology Practice"},{"issue":"6","key":"10.1002\/14651858.CD003407.pub5-BIB0306|cit306","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S1548-5315(12)70022-0","article-title":"IV iron sucrose for cancer and\/or chemotherapy-induced anemia in patients treated with erythropoiesisstimulating agents","volume":"8","author":"Anthony","year":"2011","journal-title":"Community Oncology"},{"issue":"11","key":"10.1002\/14651858.CD003407.pub5-BIB0307|cit307","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.3324\/haematol.2010.030213","article-title":"Non-erythroid effects of erythropoietin","volume":"95","author":"Arcasoy","year":"2010","journal-title":"Haematologica"},{"issue":"4","key":"10.1002\/14651858.CD003407.pub5-BIB0308|cit308","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1177\/030089160409000406","article-title":"Comparison of clinical outcomes of different erythropoietin usage strategies","volume":"90","author":"Arslan","year":"2004","journal-title":"Tumori"},{"issue":"7","key":"10.1002\/14651858.CD003407.pub5-BIB0309|cit309","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.2004.08.119","article-title":"Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial","volume":"22","author":"Auerbach","year":"2004","journal-title":"Journal of Clinical Oncology"},{"issue":"1076","key":"10.1002\/14651858.CD003407.pub5-BIB0310|cit310","first-page":"62","article-title":"Erythropoiesis-stimulating agents increase mortality in cancer patients","volume":"91","author":"Australian","year":"2010","journal-title":"Australian Journal of Pharmacy"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0311|cit311","doi-asserted-by":"crossref","unstructured":"Aziz K Hashem T Mobarek N Bary N Ghoneimy I Haddad S Does recombinant human erythropoietin improve the outcome of radiation therapy in head and neck cancer Patients Proceedings of ASTRO 2001","DOI":"10.1016\/S0360-3016(01)02503-2"},{"issue":"0007-0920 (Prin","key":"10.1002\/14651858.CD003407.pub5-BIB0312|cit312","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/bjc.1998.579","article-title":"Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia","volume":"78","author":"Barosi","year":"1998","journal-title":"British Journal of Cancer"},{"issue":"7","key":"10.1002\/14651858.CD003407.pub5-BIB0313|cit313","doi-asserted-by":"crossref","first-page":"937","DOI":"10.3324\/haematol.2011.041210","article-title":"Key concepts and critical issues on epoetin and filgrastim biosimilars: A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation","volume":"96","author":"Barosi","year":"2011","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0314|cit314","doi-asserted-by":"crossref","unstructured":"Beggs VL Disalvo WM Meyer LP Gragnev KH Gibson JJ Hoopes PJ Fatigue and plasma cytokines in a randomized double-blind placebo-controlled trial of epoetin alfa in patients undergoing combined modality therapy for unreseactable non-small cell lung cancer (NSCLC) Proceedings of the American Society of Clincal Oncology 2003 733","DOI":"10.1016\/S0169-5002(03)92207-0"},{"issue":"10","key":"10.1002\/14651858.CD003407.pub5-BIB0315|cit315","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/j.1445-5994.2008.01736.x","article-title":"Outcomes and predicting response in anaemic chemotherapy patients treated with epoetin alfa. A multicentre, 4-month, open-label study in Australia and New Zealand","volume":"38","author":"Bell","year":"2008","journal-title":"Internal Medicine Journal"},{"issue":"4","key":"10.1002\/14651858.CD003407.pub5-BIB0316|cit316","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1600-0609.1997.tb01665.x","article-title":"Treatment of the anemia of aplastic anemia patients with recombinant human erythropoietin in combination with granulocyte colony-stimulating factor: a multicenter randomized controlled study. Multicenter Study Group","volume":"58","author":"Bessho","year":"1997","journal-title":"European Journal of Haematology"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0317|cit317","doi-asserted-by":"crossref","unstructured":"Bindi M Montemaggi M Sabatino M Paolelli LPR Morelli R Piazza D Reticulocytes can represent an early indicator of te erythropoietic response to darbepoetin alfa in the anemia by chemotherapy Journal of Clinical Oncology 2004 #8245","DOI":"10.1200\/jco.2004.22.90140.8245"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0318|cit318","unstructured":"Blayney D Fesen M Mirtsching BC Katz D Tomita D Every-2-Week Darbepoetin Alfa improves hemoglobin in anemic patients with cancer undergoing chemotherapy: A stratified analysis by tumor type Blood 2003 abstract 3779"},{"issue":"1083-7159 (Prin","key":"10.1002\/14651858.CD003407.pub5-BIB0319|cit319","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1634\/theoncologist.12-5-584","article-title":"The effectiveness of darbepoetin alfa administered every 3 weeks on hematologic outcomes and quality of life in older patients with chemotherapy-induced anemia","volume":"12","author":"Boccia","year":"2007","journal-title":"Oncologist."},{"issue":"6","key":"10.1002\/14651858.CD003407.pub5-BIB0320|cit320","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1080\/02841860701744498","article-title":"The cost-effectiveness of treatment with erythropoietin compared to red blood cell transfusions for patients with chemotherapy induced anaemia: a Markov model","volume":"47","author":"Borg","year":"2008","journal-title":"Acta Oncologica"},{"issue":"4","key":"10.1002\/14651858.CD003407.pub5-BIB0321|cit321","first-page":"465","article-title":"[Cost-effectiveness of darbepoetin alpha in an every-3-weeks schedule]. [French]","volume":"95","author":"Borget","year":"2008","journal-title":"Bulletin du Cancer"},{"issue":"11","key":"10.1002\/14651858.CD003407.pub5-BIB0322|cit322","first-page":"1435","article-title":"Prediction of response to recombinant erythropoietin plus granulocyte-colony stimulating factor following a single subcutaneous bolus in patients with myelodysplastic syndromes; a randomised placebo controlled study","volume":"104","author":"Bowen","year":"2004","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"19","key":"10.1002\/14651858.CD003407.pub5-BIB0323|cit323","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1093\/jnci\/djn358","article-title":"ESAs further restricted, but debate continues","volume":"100","author":"Brower","year":"2008","journal-title":"Journal of the National Cancer Institute"},{"issue":"2","key":"10.1002\/14651858.CD003407.pub5-BIB0324|cit324","first-page":"147","article-title":"[Therapeutic equivalence and effectiveness of Binocrit (HX575) in patients with anemia caused by chemotherapy]. [Czech]","volume":"24","author":"Buchler","year":"2011","journal-title":"Klinicka Onkologie"},{"issue":"4","key":"10.1002\/14651858.CD003407.pub5-BIB0325|cit325","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/mpo.10185","article-title":"Is epoetin alfa a treatment option for chemotherapy-related anemia in children?","volume":"39","author":"Buyukpamukcu","year":"2002","journal-title":"Medical and Pediatric Oncology"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0326|cit326","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/cncr.26341","article-title":"Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia\/lymphoma: results of a randomized clinical trial","volume":"118","author":"Cabanillas","year":"2012","journal-title":"Cancer"},{"issue":"2","key":"10.1002\/14651858.CD003407.pub5-BIB0327|cit327","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1385\/MO:22:2:161","article-title":"Anemia in cervical cancer patients: implications for iron supplementation therapy","volume":"22","author":"Candelaria","year":"2005","journal-title":"Medical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD003407.pub5-BIB0328|cit328","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/jnci\/djj053","article-title":"Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia","volume":"98","author":"Canon","year":"2006","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0329|cit329","doi-asserted-by":"crossref","unstructured":"Canon JL Vansteenkiste J Bodoky G Mateos MV Bastit L Ferreira I Results of a randomised, double-blind, active-controlled trial of darbepoetin alfa administered once every 3 weeks for the treatment of anaemia in patients receiving multicycle chemotherapy Haematologica 2005 abstract 471","DOI":"10.1200\/jco.2005.23.16_suppl.lba8284"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0330|cit330","first-page":"1","article-title":"Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of <9 g\/dL versus 9 to <10 g\/dL versus (greater-than or equal to)10 g\/dL: an exploratory analysis of a phase 3 trial","volume":"xx","author":"Canon","year":"2011","journal-title":"Medical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD003407.pub5-BIB0331|cit331","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s12185-009-0378-2","article-title":"High-dose epoetin alfa as induction treatment for severe anemia in multiple myeloma patients","volume":"90","author":"Caravita","year":"2009","journal-title":"International Journal of Hematology"},{"issue":"2","key":"10.1002\/14651858.CD003407.pub5-BIB0332|cit332","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1182\/blood-2003-07-2252","article-title":"Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial","volume":"104","author":"Casadevall","year":"2004","journal-title":"Blood"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0333|cit333","unstructured":"Casadevall N Lepage E Durieux P Dubois S Dreyfus F Quarre MC Erythropoietin (RHUEPO) plus G-CSF in the treatment of anemia in myelodysplastic syndromes (MDS): results of a randomised trial with impact on quality of life and costs The Hematology Journal 2001 abstract 687"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0334|cit334","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1046\/j.1365-2141.2003.04439.x","article-title":"Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production","volume":"122","author":"Cazzola","year":"2003","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0335|cit335","unstructured":"Cazzola M Coiffier B Kloczko J Spika I Once weekly NeoRecormon\u00ae (epoetin beta) for the treatment of anemia associated with lymphoproliferative malignancies: results of the NOW (NeoRecormon\u00ae once weekly) study Hematology Journal 2002 abstract 0182"},{"issue":"4","key":"10.1002\/14651858.CD003407.pub5-BIB0336|cit336","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0936-6555(05)80622-3","article-title":"Recombinant human erythropoietin for anaemia in Chinese cancer patients on chemotherapy","volume":"7","author":"Chan","year":"1995","journal-title":"Clinical Oncology (Royal College of Radiologists)"},{"issue":"1","key":"10.1002\/14651858.CD003407.pub5-BIB0337|cit337","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11655-009-0063-3","article-title":"Clinical observation on the treatment of male neoplastic anemia with Yixuesheng capsule combined with recombination human erythropoietin","volume":"15","author":"Cheng","year":"2009","journal-title":"Chinese Journal of Integrative Medicine"},{"issue":"9","key":"10.1002\/14651858.CD003407.pub5-BIB0338|cit338","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1245\/ASO.2005.06.031","article-title":"Preoperative epoetin alfa in colorectal surgery: a randomized, controlled study","volume":"12","author":"Christodoulakis","year":"2005","journal-title":"Annals of Surgical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD003407.pub5-BIB0339|cit339","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3816\/SCT.2006.n.031","article-title":"Effect of treatment with epoetin Beta on thromboembolic events in anemic patients with cancer: a metaanalysis","volume":"4","author":"Coiffier","year":"2006","journal-title":"Supportive Cancer Therapy"},{"issue":"15","key":"10.1002\/14651858.CD003407.pub5-BIB0340|cit340","doi-asserted-by":"crossref","first-page":"9554","DOI":"10.1200\/jco.2009.27.15_suppl.9554","article-title":"Predictors of deep vein thrombosis (DVT) in newly diagnosed multiple myeloma (MM) patients with and without prophylactic recombinant erythropoietin (EPO) therapy","volume":"27","author":"Coleman","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0341|cit341","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0169-5002(97)80173-0","article-title":"Prevention of chemotherapy-related anemia by recombinant human erythropoietin (EPO) in patients with small cell lung cancer receiving cyclophosphamide, doxorubicin, and etoposide (CAE) chemotherapy with G-CSF support","volume":"18 Suppl 1","author":"Crawford","year":"1997","journal-title":"Lung Cancer"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0342|cit342","unstructured":"Crawford J Robert F Perry M Belani CP Sarokhan B Epoetin alfa 40,000 u once weekly maintains hemoglobin in advanced non-small-cell lung cancer patients receiving first-line chemotherapy Proceedings of the American Society of Clinical Oncology 2003 628"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0343|cit343","first-page":"628, abstract 2","article-title":"Epoetin alfa 40,000 u once weekly maintains hemoglobin in advanced non-small-cell lung cancer patients receiving first-line chemotherapy","volume":"22","author":"Crawford","year":"2003","journal-title":"Proceedings of the American Society of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0344|cit344","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/JTO.0b013e318031cd9a","article-title":"A randomized trial comparing immediate versus delayed treatment of anemia with once-weekly epoetin alfa in patients with non-small cell lung cancer scheduled to receive first-line chemotherapy","volume":"2","author":"Crawford","year":"2007","journal-title":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0345|cit345","unstructured":"Cremieux P Greenberg P Piech CT Epoetin alfa is more effective and less costly relative to darbepoetin alfa in lung cancer patients receiving treatment for chemotherapy-induced anemia [abstract no. 2248] Proceedings of the American Society of Clinical Oncology 2003 2248"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0346|cit346","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1525-139X.2008.00435.x","article-title":"Thrombosis with erythropoietic stimulating agents-does iron-deficient erythropoiesis play a role?","volume":"21","author":"Dahl","year":"2008","journal-title":"Seminars in Dialysis"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0347|cit347","first-page":"5374","article-title":"Protection of metabolic and exercise capacity in unselected weight-losing cancer patients following treatment with recombinant erythropoietin: a randomized prospective study","volume":"58","author":"Daneryd","year":"1998","journal-title":"Cancer Research"},{"issue":"20","key":"10.1002\/14651858.CD003407.pub5-BIB0348|cit348","doi-asserted-by":"crossref","first-page":"6855","DOI":"10.1158\/1078-0432.CCR-04-0373","article-title":"Effects of recombinant erythropoietin in palliative treatment of unselected cancer patients","volume":"10","author":"Lindholm","year":"2004","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"10.1002\/14651858.CD003407.pub5-BIB0349|cit349","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s12032-007-9001-7","article-title":"Survival and erythropoietin receptor protein in tumours from patients randomly treated with rhEPO for palliative care","volume":"25","author":"Lonnroth","year":"2008","journal-title":"Medical Oncology"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0350|cit350","doi-asserted-by":"crossref","unstructured":"Dannemann B Wacholtz M Lau H Cheung W Pharmacokinetics (PK) and pharmacodynamics (PD) of epoetin alfa in cancer patients with anemia receiving cyclic chemotherapy Journal of Clinical Oncology 2004 775, abstract 8203","DOI":"10.1200\/jco.2004.22.14_suppl.8203"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0351|cit351","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.1998.16.10.3412","article-title":"Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study","volume":"16","author":"Demetri","year":"1998","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD003407.pub5-BIB0352|cit352","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s12094-011-0655-4","article-title":"Erythropoiesis-stimulating agents: The present situation","volume":"13","author":"Dicato","year":"2011","journal-title":"Clinical and Translational Oncology"},{"issue":"9","key":"10.1002\/14651858.CD003407.pub5-BIB0353|cit353","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/ncponc1202","article-title":"VTE and mortality associated with erythropoiesis-stimulating agents in cancer-associated anemia.[comment]","volume":"5","author":"Dronca","year":"2008","journal-title":"Nature Clinical Practice Oncology"},{"issue":"5","key":"10.1002\/14651858.CD003407.pub5-BIB0354|cit354","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/0360-3016(94)90403-0","article-title":"Erythropoietin increases hemoglobin during radiation therapy for cervical cancer","volume":"29","author":"Dusenbery","year":"1994","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0355|cit355","doi-asserted-by":"crossref","unstructured":"Elsaid A Farouk M Significance of anemia and role of erythropoietin in radiation induced mucositis in head and neck cancer patients International Journal of Radiation Oncology Biology Physics 2001 368","DOI":"10.1016\/S0360-3016(01)02504-4"},{"issue":"0941-4355 (Prin","key":"10.1002\/14651858.CD003407.pub5-BIB0356|cit356","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1007\/s00520-006-0062-5","article-title":"Clinical and economic impact of epoetin in adjuvant-chemotherapy for breast cancer","volume":"14","author":"Fagnoni","year":"2006","journal-title":"Support.Care Cancer"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0357|cit357","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1365-2141.2008.07465.x","article-title":"Efficacy of a combination of human recombinant erythropoietin + 13-cis-retinoic acid and dihydroxylated vitamin D3 to improve moderate to severe anaemia in low\/intermediate risk myelodysplastic syndromes","volume":"144","author":"Ferrero","year":"2009","journal-title":"British Journal of Haematology"},{"issue":"4","key":"10.1002\/14651858.CD003407.pub5-BIB0358|cit358","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10238-008-0003-3","article-title":"Darbepoetin in the control of cancer-related anaemia","volume":"8","author":"Franchi","year":"2008","journal-title":"Clinical & Experimental Medicine"},{"issue":"5","key":"10.1002\/14651858.CD003407.pub5-BIB0359|cit359","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/pbc.20685","article-title":"Pharmacokinetics and pharmacodynamics of intravenous epoetin alfa in children with cancer","volume":"47","author":"Freeman III","year":"2006","journal-title":"Pediatric Blood & Cancer"},{"issue":"8","key":"10.1002\/14651858.CD003407.pub5-BIB0360|cit360","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/jjco\/hyl074","article-title":"Pharmacokinetics and pharmacodynamics of weekly epoetin beta in lung cancer patients","volume":"36","author":"Fujisaka","year":"2006","journal-title":"Japanese Journal of Clinical Oncology"},{"issue":"11","key":"10.1002\/14651858.CD003407.pub5-BIB0361|cit361","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2001.19.11.2875","article-title":"Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing","volume":"19","author":"Gabrilove","year":"2001","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0362|cit362","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1001\/archinte.1995.00430190059008","article-title":"Epoetin alfa for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo-controlled, double-blind trial","volume":"155","author":"Garton","year":"1995","journal-title":"Archives of Internal Medicine"},{"issue":"SUPPL. 3","key":"10.1002\/14651858.CD003407.pub5-BIB0363|cit363","first-page":"4","article-title":"Safety update on erythropoiesis-stimulating agents: Trials within and outside the accepted indications","volume":"13","author":"Gascn","year":"2008","journal-title":"unknown AM"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0364|cit364","first-page":"341","article-title":"Subcutaneous recombinant human erythropoietin prevents chemotherapy-related anemia in patients with advanced cancer","volume":"1","author":"Gebbia","year":"1992","journal-title":"International Journal of Oncology"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0365|cit365","first-page":"Abstract 1543","article-title":"R-HuErythropoietin treatment increases efficacy of neo-adjuvant radiochemotherapy and improves cancer free survival of patient with oral squamous cell carcinoma: a 17 months follow-up","volume":"Meeting Abstrac","author":"Glaser","year":"1999","journal-title":"ASCO"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0366|cit366","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0360-3016(01)01488-2","article-title":"Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx","volume":"50","author":"Glaser","year":"2001","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0367|cit367","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1200\/JCO.1997.15.3.1218","article-title":"Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice","volume":"15","author":"Glaspy","year":"1997","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0368|cit368","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1054\/bjoc.2001.1748","article-title":"A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy","volume":"84 Suppl 1","author":"Glaspy","year":"2001","journal-title":"British Journal of Cancer"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0369|cit369","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/sj.bjc.6600465","article-title":"Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy","volume":"87","author":"Glaspy","year":"2002","journal-title":"British Journal of Cancer"},{"issue":"10 Suppl 11","key":"10.1002\/14651858.CD003407.pub5-BIB0370|cit370","first-page":"23","article-title":"Darbepoetin alfa administered every 2 weeks alleviates anemia in cancer patients receiving chemotherapy","volume":"16","author":"Glaspy","year":"2002","journal-title":"Oncology (Huntingt)"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0371|cit371","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1002\/cncr.11186","article-title":"A randomized, active-control, pilot trial of front-loaded dosing regimens of darbeopetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease","volume":"97","author":"Glaspy","year":"2003","journal-title":"Cancer"},{"issue":"8","key":"10.1002\/14651858.CD003407.pub5-BIB0372|cit372","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.ejca.2005.01.021","article-title":"Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: A randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa","volume":"41","author":"Glaspy","year":"2005","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0373|cit373","unstructured":"Glaspy J Jadeja J Justice G Fleishman A Rossi G Colowick A Optimizing the management of anemia in patients with cancer: a randomized, active-controlled, study investigating the dosing of darbepoetin alfa Hematology Journal 2002 abstract 0109"},{"issue":"15","key":"10.1002\/14651858.CD003407.pub5-BIB0374|cit374","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1200\/JCO.2005.03.8570","article-title":"Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial","volume":"24","author":"Glaspy","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD003407.pub5-BIB0375|cit375","first-page":"423","article-title":"Darbepoetin Alfa controversies, from dosage issues to safety concerns: The larger lesson","volume":"25","author":"Glaspy","year":"2011","journal-title":"Oncology"},{"issue":"2","key":"10.1002\/14651858.CD003407.pub5-BIB0376|cit376","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1200\/JCO.1998.16.2.434","article-title":"Epoetin beta in the treatment of anemia in patients with advanced gastrointestinal cancer","volume":"16","author":"Glimelius","year":"1998","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD003407.pub5-BIB0377|cit377","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00277-003-0695-0","article-title":"Recombinant human erythropoietin, epoetin beta, in patients with relapsed lymphoma treated with aggressive sequential salvage chemotherapy - results of a randomized trial","volume":"82","author":"Glossmann","year":"2003","journal-title":"Annals of Hematology"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0378|cit378","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/ki.2011.133","article-title":"Significant further evidence to bolster the link between epoetin and strokes in chronic kidney disease and cancer","volume":"80","author":"Goldsmith","year":"2011","journal-title":"Kidney International"},{"issue":"5","key":"10.1002\/14651858.CD003407.pub5-BIB0379|cit379","first-page":"1289","article-title":"Comparing the efficacy and safety of fixed versus weight-based dosing of epoetin alpha in anemic cancer patients receiving platinum-based chemotherapy","volume":"10","author":"Granetto","year":"2003","journal-title":"Oncology Reports"},{"issue":"4","key":"10.1002\/14651858.CD003407.pub5-BIB0380|cit380","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3816\/SCT.2006.n.021","article-title":"Efficacy of darbepoetin alfa in the treatment of chemotherapy-induced anemia in non-Hodgkin's lymphoma","volume":"3","author":"Gregory","year":"2006","journal-title":"Supportive Cancer Therapy"},{"issue":"Supplement 9","key":"10.1002\/14651858.CD003407.pub5-BIB0381|cit381","first-page":"ix295 Abstract","article-title":"Platinum-based chemotherapy for patients (PT) with non small cell lung cancer (NSCLC) with anemia treated with epoetin beta or blood transfusions, a pilot study","volume":"17","author":"Grigorescu","year":"2006","journal-title":"Annals of Oncology"},{"issue":"25","key":"10.1002\/14651858.CD003407.pub5-BIB0382|cit382","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1200\/JCO.2008.21.6945","article-title":"Erythroid-stimulating agents in cancer therapy: potential dangers and biologic mechanisms","volume":"27","author":"Hadland","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10.1002\/14651858.CD003407.pub5-BIB0383|cit383","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/cncr.23790","article-title":"Randomized phase 2 study of subcutaneous amifostine versus epoetin-alpha given 3 times weekly during concurrent chemotherapy and hyperfractionated radiotherapy for limited-disease small cell lung cancer","volume":"113","author":"Han","year":"2008","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0384|cit384","doi-asserted-by":"crossref","unstructured":"Harousseau JL Fumoleau P Lange W Welslau M Increasing hemoglobin levels with epoetin alfa in anemic hematologic cancer patients receiving chemotherapy correlates significantly with improved quality of life Blood 2004 2213","DOI":"10.1182\/blood.V104.11.2213.2213"},{"issue":"7","key":"10.1002\/14651858.CD003407.pub5-BIB0385|cit385","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.3109\/10428194.2010.496020","article-title":"Erythropoiesis-stimulating agents in myelodysplastic syndromes","volume":"51","author":"Hellstrm-Lindberg","year":"2010","journal-title":"Leukemia and Lymphoma"},{"issue":"1","key":"10.1002\/14651858.CD003407.pub5-BIB0386|cit386","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1182\/blood.V92.1.68.413k23_68_75","article-title":"Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients","volume":"92","author":"Hellstr\u00f6m Lindberg","year":"1998","journal-title":"Blood"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0387|cit387","doi-asserted-by":"crossref","unstructured":"Henry DH Dahl NV Auerbach M Tchekmedyian S Laufman LR Intravenous ferric gluconate (FG) for increasing response to epoetin (EPO) in patients with anemia of cancer chemotherapy results of a multicenter, randomized trial Blood 2004 10b, abstract 3696","DOI":"10.1182\/blood.V104.11.3696.3696"},{"issue":"7","key":"10.1002\/14651858.CD003407.pub5-BIB0388|cit388","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1185\/030079906X115559","article-title":"Randomized, open-label comparison of epoetin alfa extended dosing (80 000 U Q2W) vs weekly dosing (40 000 U QW) in patients with chemotherapy-induced anemia","volume":"22","author":"Henry","year":"2006","journal-title":"Current Medical Research & Opinion"},{"issue":"4 Suppl 2","key":"10.1002\/14651858.CD003407.pub5-BIB0389|cit389","first-page":"16","article-title":"Randomized, open-label comparison of epoetin alfa extended dosing (80,000 U every two weeks) versus weekly dosing (40,000 U weekly) in anemic patients with cancer receiving chemotherapy","volume":"5","author":"Henry","year":"2007","journal-title":"Journal of Supportive Oncology"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0391|cit390","doi-asserted-by":"crossref","unstructured":"Henry DH Dahl NV Auerbach M Is thromboembolism in cancer patients treated with erythropoietic stimulating agents related to thrombocytosis and iron restricted erythropoiesis? Blood 2007 abstract 1625","DOI":"10.1182\/blood.V110.11.1625.1625"},{"issue":"2","key":"10.1002\/14651858.CD003407.pub5-BIB0390|cit391","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1634\/theoncologist.12-2-231","article-title":"Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy","volume":"12","author":"Henry","year":"2007","journal-title":"Oncologist"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0392|cit392","unstructured":"Henze G Michon J Morland B Perek D Rizzari C Zoubek A EPO INT51 Study Group Phase III randomized study: efficacy of epoetin alfa in reducing blood transfusions in newly diagnosed pediatric cancer patients receiving chemotherapy 2002 ASCO Annual Meeting 2002"},{"issue":"4","key":"10.1002\/14651858.CD003407.pub5-BIB0393|cit393","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/cncr.11954","article-title":"A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies","volume":"100","author":"Hesketh","year":"2004","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0394|cit394","unstructured":"Hesketh PJ Arena F Patel D Poulsen E D'Avirro P Rossi G Front-loaded darbepoetin alfa with Q3W maintenance administered as a fixed or weight-based dose in anemic cancer patients results in similar efficacy profiles Proceedings of the American Society of Clinical Oncology 2003 abstract 2941"},{"issue":"1745-6215 (Elec","key":"10.1002\/14651858.CD003407.pub5-BIB0395|cit395","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1745-6215-8-8","article-title":"Phase II study of two dose schedules of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in anemic patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy","volume":"8","author":"Hirsh","year":"2007","journal-title":"Trials"},{"issue":"7","key":"10.1002\/14651858.CD003407.pub5-BIB0396|cit396","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nbt.1913","article-title":"Public biotech 2010-the numbers","volume":"29","author":"Huggett","year":"2011","journal-title":"Nature Biotechnology"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0397|cit397","first-page":"35","article-title":"Serum hepcidin levels predict ESA and IV iron responses","volume":"July-August","author":"Hyer","year":"2011","journal-title":"Oncology Report"},{"issue":"4","key":"10.1002\/14651858.CD003407.pub5-BIB0398|cit398","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/leu.2008.362","article-title":"Is there a role for all-trans retinoic acid in combination with recombinant erythropoetin in myelodysplastic syndromes? A report on 59 cases","volume":"23","author":"Itzykson","year":"2009","journal-title":"Leukemia"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0399|cit399","unstructured":"Jacubowski AA Hurria A Williams D Head-to-head comparison of epoetin alfa 40,000 QW vs darbepoetin alfa 200 mcg Q2W in anemic patients with cancer receiving chemotherapy: preliminary results Blood 2003 #4391"},{"issue":"21","key":"10.1002\/14651858.CD003407.pub5-BIB0400|cit400","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1200\/JCO.2007.15.4906","article-title":"Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome","volume":"26","author":"Jadersten","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD003407.pub5-BIB0401|cit401","first-page":"283","article-title":"Impact of therapy with recombinant human erythropoietin (r-HuEPO) and Quality-of-life in anemic cancer patients","volume":"17","author":"Jitnuyanont","year":"2001","journal-title":"Internal Medicine Journal of Thailand"},{"issue":"4","key":"10.1002\/14651858.CD003407.pub5-BIB0402|cit402","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1080\/003655901750425864","article-title":"Efficacy of epoetin beta on hemoglobin, quality of life, and transfusion needs in patients with anemia due to hormone-refractory prostate cancer--a randomized study","volume":"35","author":"Johansson","year":"2001","journal-title":"Scandinavian Journal of Urology & Nephrology"},{"issue":"11","key":"10.1002\/14651858.CD003407.pub5-BIB0403|cit403","first-page":"23","article-title":"Palliative care in advanced cancer in older adults: management of pain, fatigue, and gastrointestinal symptoms","volume":"19","author":"Jones","year":"2011","journal-title":"Clinical Geriatrics"},{"issue":"Supplement 9","key":"10.1002\/14651858.CD003407.pub5-BIB0404|cit404","first-page":"ix293 Absrtact","article-title":"Clinical benefit associated with early erythropoietic intervention in chemotherapy induced anemia","volume":"17","author":"Juan","year":"2006","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0405|cit405","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1093\/annonc\/mdi218","article-title":"A randomized, multicenter study of subcutaneous and intravenous darbepoetin alfa for the treatment of chemotherapy-induced anemia","volume":"16","author":"Justice","year":"2005","journal-title":"Annals of Oncology"},{"issue":"24","key":"10.1002\/14651858.CD003407.pub5-BIB0406|cit406","first-page":"2855","article-title":"Erythropoiesis-stimulating agents in the treatment of cancer-associated anemia.[comment]","volume":"300","author":"Kara","year":"2008","journal-title":"JAMA"},{"issue":"9","key":"10.1002\/14651858.CD003407.pub5-BIB0407|cit407","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/ajh.21239","article-title":"Erythropoiesis-stimulating agents are associated with reduced survival in patients with multiple myeloma.[see comment]","volume":"83","author":"Katodritou","year":"2008","journal-title":"American Journal of Hematology"},{"issue":"22","key":"10.1002\/14651858.CD003407.pub5-BIB0408|cit408","first-page":"4873","article-title":"Correlation of erythropoietin stimulating agents (ESAs) with the post-therapy micro-vessel density (MVD) in newly diagnosed myeloma patients: a possible mechanism of ESAs association with reduced survival rates","volume":"114","author":"Katodritou","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"1","key":"10.1002\/14651858.CD003407.pub5-BIB0409|cit409","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1046\/j.1365-2168.1998.00564.x","article-title":"Randomized multicentre trial of the influence of recombinant human erythropoietin on intraoperative and postoperative transfusion need in anaemic patients undergoing right hemicolectomy for carcinoma","volume":"85","author":"Kettelhack","year":"1998","journal-title":"British Journal of Surgery"},{"issue":"11","key":"10.1002\/14651858.CD003407.pub5-BIB0410|cit410","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1016\/j.clinthera.2010.10.001","article-title":"Pharmacokinetic and pharmacodynamic comparison of two recombinant human erythropoietin formulations after single subcutaneous administration: an open-label, sequence-randomized, two-treatment crossover study in healthy Korean male volunteers","volume":"32","author":"Kim","year":"2010","journal-title":"Clinical Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0411|cit411","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/01.SLA.0000055275.38740.56","article-title":"Perioperative erythropoietin administration in patients with gastrointestinal tract cancer: prospective randomized double-blind study","volume":"237","author":"Kosmadakis","year":"2003","journal-title":"Annals of Surgery"},{"issue":"11","key":"10.1002\/14651858.CD003407.pub5-BIB0412|cit412","doi-asserted-by":"crossref","first-page":"abstract 1636","DOI":"10.1182\/blood.V104.11.1636.1636","article-title":"Correction\/maintenance dosing (front loading) of darbepoetin alfa: final results from a randomized phase 3 active controlled trial","volume":"104","author":"Kotasek","year":"2004","journal-title":"Blood"},{"issue":"2 SUPPL. 1","key":"10.1002\/14651858.CD003407.pub5-BIB0413|cit413","first-page":"16","article-title":"Correction\/maintenance dosing (front loading) of darbepoetin alfa: Final results from a randomized phase III active-controlled trial","volume":"3","author":"Kotasek","year":"2005","journal-title":"The Journal of Supportive Oncology"},{"issue":"6","key":"10.1002\/14651858.CD003407.pub5-BIB0414|cit414","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1185\/030079907X188053","article-title":"A randomized, controlled trial comparing darbepoetin alfa correction\/maintenance dosing with weekly dosing for treating chemotherapy-induced anemia","volume":"23","author":"Kotasek","year":"2007","journal-title":"Current Medical Research & Opinion"},{"issue":"2","key":"10.1002\/14651858.CD003407.pub5-BIB0415|cit415","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2354.2007.00844.x","article-title":"Anemia in patients with midgut carcinoid, treated with alpha interferon: effects by erythropoietin treatment on the perceived quality of life","volume":"17","author":"Larsson","year":"2008","journal-title":"European Journal of Cancer Care"},{"issue":"0025-7680 (Prin","key":"10.1002\/14651858.CD003407.pub5-BIB0416|cit416","first-page":"41","article-title":"[Predictive response variables to recombinant human erythropoietin treatment in patients with anemia and cancer]","volume":"62","author":"Lastiri","year":"2002","journal-title":"Medicina (B Aires)"},{"issue":"2","key":"10.1002\/14651858.CD003407.pub5-BIB0417|cit417","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1159\/000166864","article-title":"Twice-weekly high-dose rHuEpo for the treatment of anemia in patients with low-risk myelodysplastic syndromes","volume":"120","author":"Latagliata","year":"2008","journal-title":"Acta Haematologica"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0418|cit418","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/0360-3016(93)90536-5","article-title":"Erythropoietin increases hemoglobin in cancer patients during radiation therapy","volume":"27","author":"Lavey","year":"1993","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"1","key":"10.1002\/14651858.CD003407.pub5-BIB0419|cit419","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ygyno.2004.07.009","article-title":"Recombinant human erythropoietin as an adjunct to radiation therapy and cisplatin for stage IIB-IVA carcinoma of the cervix: a Southwest Oncology Group study","volume":"95","author":"Lavey","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0420|cit420","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1002\/1097-0142(19940515)73:10<2535::AID-CNCR2820731014>3.0.CO;2-5","article-title":"Quality of life in chronic anaemia of cancer during treatment with recombinant human erythropoietin","volume":"73","author":"Leitgeb","year":"1994","journal-title":"Cancer"},{"issue":"2","key":"10.1002\/14651858.CD003407.pub5-BIB0421|cit421","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/(SICI)1096-911X(199802)30:2<110::AID-MPO8>3.0.CO;2-L","article-title":"Recombinant human erythropoietin for the treatment of anemia in children with solid malignant tumors","volume":"30","author":"Leon","year":"1998","journal-title":"Medical and Pediatric Oncology"},{"issue":"5","key":"10.1002\/14651858.CD003407.pub5-BIB0422|cit422","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3949\/ccjm.75.5.359","article-title":"How safe are erythropoiesis-stimulating agents?[see comment]","volume":"75","author":"Lichtin","year":"2008","journal-title":"Cleveland Clinic Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD003407.pub5-BIB0423|cit423","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3816\/SCT.2006.n.006","article-title":"Darbepoetin alfa as primary prophylaxis of anemia in patients with breast cancer treated preoperatively with docetaxel\/doxorubicin\/cyclophosphamide","volume":"3","author":"Loibl","year":"2006","journal-title":"Supportive Cancer Therapy"},{"issue":"11","key":"10.1002\/14651858.CD003407.pub5-BIB0424|cit424","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1002\/1097-0142(19951201)76:11<2319::AID-CNCR2820761121>3.0.CO;2-U","article-title":"Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy","volume":"76","author":"Ludwig","year":"1995","journal-title":"Cancer"},{"issue":"5","key":"10.1002\/14651858.CD003407.pub5-BIB0425|cit425","first-page":"127","article-title":"The effect of subcutaneous recombinant human erythropoietin (r-HuEPO) on anemia in cancer patients receiving platinum-based chemotherapy","volume":"48","author":"Malik","year":"1998","journal-title":"Journal of the Pakistan Medical Association"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0426|cit426","first-page":"177","article-title":"[Erythropoietin and cisplatin-induced neuropathies in cancer patients]. [Italian]","volume":"153","author":"Mangiameli","year":"2002","journal-title":"Clinica Terapeutica"},{"issue":"2","key":"10.1002\/14651858.CD003407.pub5-BIB0427|cit427","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1046\/j.1365-2141.2000.02016.x","article-title":"Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin","volume":"109","author":"Mantovani","year":"2000","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0428|cit428","doi-asserted-by":"crossref","unstructured":"Marinaccio M Mele E Giotta F Cantinieri C Cocca M Pretreatment normalization of mild anemia with epoetin alfa: Impact on the outcome in epithelial ovarian cancer patients Proceedings of the American Society of Clinical Oncology 2003 486","DOI":"10.1200\/jco.2004.22.90140.5132"},{"issue":"2","key":"10.1002\/14651858.CD003407.pub5-BIB0429|cit429","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1006\/gyno.1993.1102","article-title":"The use of recombinant human erythropoietin to prevent carboplatin-induced anemia","volume":"49","author":"Markman","year":"1993","journal-title":"Gynecologic Oncology"},{"issue":"10","key":"10.1002\/14651858.CD003407.pub5-BIB0430|cit430","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1185\/03007990802381323","article-title":"A prospective observational study of the effectiveness, safety, and effect on fatigue of darbepoetin alfa for the treatment of chemotherapy-induced anaemia","volume":"24","author":"Mel","year":"2008","journal-title":"Current Medical Research & Opinion"},{"issue":"2","key":"10.1002\/14651858.CD003407.pub5-BIB0431|cit431","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1365-2141.2009.07702.x","article-title":"Biological functions and therapeutic use of erythropoiesis-stimulating agents: perplexities and perspectives","volume":"146","author":"Merchionne","year":"2009","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0432|cit432","doi-asserted-by":"crossref","unstructured":"Merlano M Ricci S Martoni A Comparing the efficacy of fixed vs. weight-based dosing of epoetin alfa in anemic cancer patients receiving platinum-based chemotherapy European Journal of Cancer 2001 S346","DOI":"10.1016\/S0959-8049(01)81776-7"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0433|cit433","unstructured":"Luksenburg H Weir A Wager R MF4266 in: Safety Concerns Associated with Aranesp (darbepoetin alfa) Amgen, Inc. and Procrit (epoetin alfa) Ortho Biotech, L.P., for the Treatment of Anemia Associated with Cancer Chemotherapy Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research, Oncologic Drugs Advisory Committee, Rockville (MD), USA, 2004"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0434|cit434","doi-asserted-by":"crossref","unstructured":"Miller KB Kim HT Greenberg P Van der Jagt R Bennett JM Tallman MS Phase III prospective randomized trial of EPO with or without G-CSF versus supportive therapy alone in the treatment of myelodysplastic syndromes (MDS): Results of the ECOG-CLSG trial (E1996) Blood 2004 70","DOI":"10.1182\/blood.V104.11.70.70"},{"issue":"10","key":"10.1002\/14651858.CD003407.pub5-BIB0435|cit435","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/jjco\/hyl097","article-title":"Once-weekly epoetin-beta improves hemoglobin levels in cancer patients with chemotherapy-induced anemia: A randomized, double-blind, dose-finding study","volume":"36","author":"Morishima","year":"2006","journal-title":"Japanese Journal of Clinical Oncology"},{"issue":"SUPPL. 1","key":"10.1002\/14651858.CD003407.pub5-BIB0436|cit436","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1634\/theoncologist.12-S1-1","article-title":"Cancer-related fatigue: Causes, consequences, and management","volume":"12","author":"Morrow","year":"2007","journal-title":"The Oncologist"},{"issue":"1","key":"10.1002\/14651858.CD003407.pub5-BIB0437|cit437","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3233\/CH-2009-1153","article-title":"Hemorheological changes in solid tumor patients after treatment with recombinant erythropoetin","volume":"41","author":"Muravyov","year":"2009","journal-title":"Clinical Hemorheology & Microcirculation"},{"issue":"2","key":"10.1002\/14651858.CD003407.pub5-BIB0438|cit438","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3233\/CH-2010-1259","article-title":"Comparative efficiency and hemorheological consequences of hemotransfusion and epoetin therapy in anemic cancer patients","volume":"44","author":"Muravyov","year":"2010","journal-title":"Clinical Hemorheology & Microcirculation"},{"issue":"0923-7534 (Prin","key":"10.1002\/14651858.CD003407.pub5-BIB0439|cit439","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1093\/annonc\/mdl297","article-title":"An induction dose of epoetin alpha of 40 000 IU daily for three consecutive days increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy","volume":"17","author":"Mustacchi","year":"2006","journal-title":"Annals of Oncology"},{"issue":"1","key":"10.1002\/14651858.CD003407.pub5-BIB0440|cit440","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3816\/CLC.2011.n.009","article-title":"Addition of darbepoetin alfa to dose-dense chemotherapy: Results from a randomized phase II trial in small-cell lung cancer patients receiving carboplatin plus etoposide","volume":"12","author":"Nagel","year":"2011","journal-title":"Clinical Lung Cancer"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0441|cit441","unstructured":"NCT00364845 A randomised single-blind study to improve health-related quality of life as measured by the sf-36 vitality score by correcting anemia with aranesp (darbepoetin alfa) in the elderly clinicaltrials.gov.\/ct2.\/show\/NCT00364845. 2011"},{"issue":"9686","key":"10.1002\/14651858.CD003407.pub5-BIB0442|cit442","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0140-6736(09)61356-8","article-title":"Epoetins and mortality in patients with cancer.[comment]","volume":"374","author":"Nonoguchi","year":"2009","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0443|cit443","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1055\/s-2005-858478","article-title":"Prevention and therapy of anemia in tumor patients with epoetin beta (NeoRecormon\u00ae)","volume":"26","author":"Oberhoff","year":"2005","journal-title":"Tumordiagnostik & Therapie"},{"issue":"6","key":"10.1002\/14651858.CD003407.pub5-BIB0444|cit444","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1080\/02841860214960","article-title":"Erythropoietin treatment in metastatic breast cancer--effects on Hb, quality of life and need for transfusion","volume":"41","author":"Olsson","year":"2002","journal-title":"Acta Oncologica"},{"issue":"19","key":"10.1002\/14651858.CD003407.pub5-BIB0445|cit445","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1136\/heartjnl-2011-300411","article-title":"Erythropoietin as a cardioprotective agent: Down but not out","volume":"97","author":"Opie","year":"2011","journal-title":"Heart"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0446|cit446","doi-asserted-by":"crossref","first-page":"393","DOI":"10.4137\/CMO.S510","article-title":"Darbepoetin versus epoetin alfa for the correction of anemia in cancer patients receiving radiotherapy or chemoradiotherapy treatment","volume":"2","author":"Ots","year":"2008","journal-title":"Clinical Medicine Oncology"},{"issue":"2","key":"10.1002\/14651858.CD003407.pub5-BIB0447|cit447","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00520-008-0517-y","article-title":"Observational Aranesp Survey to Investigate the Q3W Schedule (OASIS): a prospective observational study of treatment of chemotherapy-induced anaemia with every 3 weeks darbepoetin alfa","volume":"17","author":"Pat","year":"2009","journal-title":"Supportive Care in Cancer"},{"issue":"4","key":"10.1002\/14651858.CD003407.pub5-BIB0448|cit448","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.1999.17.4.1288","article-title":"Erythropoietin addition to granulocyte colony-stimulating factor abrogates life-threatening neutropenia and increases peripheral-blood progenitor-cell mobilization after epirubicin, paclitaxel, and cisplatin combination chemotherapy: results of a randomized comparison","volume":"17","author":"Pierelli","year":"1999","journal-title":"Journal of Clinical Oncology"},{"issue":"5-6","key":"10.1002\/14651858.CD003407.pub5-BIB0449|cit449","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.tracli.2010.09.162","article-title":"[Oncology blood transfusion and quality of life: review]","volume":"17","author":"Poirier","year":"2010","journal-title":"Transfusion Clinique et Biologique"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0450|cit450","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S1548-5315(11)70071-7","article-title":"Epoetin alfa for chemotherapy-induced anemia: Assessment of two equivalent dosing regimens","volume":"4","author":"Policarpo","year":"2007","journal-title":"Community Oncology"},{"issue":"2","key":"10.1002\/14651858.CD003407.pub5-BIB0451|cit451","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000276978","article-title":"Rapid anaemia control with epoetin: results of a Swiss survey on treatment of chemotherapy-induced anaemia","volume":"123","author":"Popescu","year":"2010","journal-title":"Acta Haematologica"},{"issue":"5","key":"10.1002\/14651858.CD003407.pub5-BIB0452|cit452","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/S0022-3476(96)70145-2","article-title":"Recombinant human erythropoietin reduces the need for erythrocyte and platelet transfusions in pediatric patients with sarcoma: A randomized, double-blind, placebo-controlled trial","volume":"129","author":"Porter","year":"1996","journal-title":"Journal of Pediatrics"},{"issue":"2","key":"10.1002\/14651858.CD003407.pub5-BIB0453|cit453","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.critrevonc.2008.07.010","article-title":"Effect of age on hemoglobin levels and quality of life following treatment with epoetin alfa in cancer patients","volume":"69","author":"Puglisi","year":"2009","journal-title":"Critical Reviews in Oncology-Hematology"},{"issue":"2","key":"10.1002\/14651858.CD003407.pub5-BIB0454|cit454","first-page":"91","article-title":"Erythropoietin administration during radiotherapy in anaemic head-and-neck cancer patients: Is it still a reasonable option or too dangerous?","volume":"45","author":"Rades","year":"2009","journal-title":"Oral"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0455|cit455","first-page":"20","article-title":"Iron and erythropoiesis-stimulating agents in anaemia","volume":"4","author":"Rath","year":"2010","journal-title":"European Journal of Oncology Pharmacy"},{"issue":"7","key":"10.1002\/14651858.CD003407.pub5-BIB0456|cit456","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/S0959-8049(98)00021-5","article-title":"Increased autologous blood donation in rectal cancer by recombinant human erythropoietin (rhEPO)","volume":"34","author":"Rau","year":"1998","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0457|cit457","doi-asserted-by":"crossref","unstructured":"Charu V Saidman B Ben-Jacob A Justice GR Maniam AS Rearden T Improvements in fatigue are associated with early treatment with darbepoetin alfa every 3 weeks (Q3W) Darbepoetin alfa (DA) treatment in anemic patients (pts) receiving chemotherapy Blood 2004 abstract 233","DOI":"10.1182\/blood.V104.11.233.233"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0458|cit458","doi-asserted-by":"crossref","unstructured":"Rearden T Charu V Saidman B Justice GR Manaim AS Results of a randomized study of every three-week dosing (Q3W) of darbepoetin alfa for chemotherapy-induced anemia (CIA) Blood 2003 abstract 3783","DOI":"10.1200\/jco.2004.22.14_suppl.8064"},{"issue":"14 Suppl","key":"10.1002\/14651858.CD003407.pub5-BIB0459|cit459","doi-asserted-by":"crossref","first-page":"abstract 8064","DOI":"10.1200\/jco.2004.22.90140.8064","article-title":"Results of a randomized study of every three-week dosing (Q3W) of darbepoetin alfa for chemotherapy-induced anemia (CIA)","volume":"22","author":"Rearden","year":"2004","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"10.1002\/14651858.CD003407.pub5-BIB0460|cit460","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1185\/030079905X65394","article-title":"Early hemoglobin response and alternative metrics of efficacy with erythropoietic agents for chemotherapy-related anemia","volume":"21","author":"Reed","year":"2005","journal-title":"Current Medical Research & Opinion"},{"issue":"1","key":"10.1002\/14651858.CD003407.pub5-BIB0461|cit461","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.leukres.2008.06.004","article-title":"Erythropoietin and cancer, a double-edged sword","volume":"33","author":"Ribatti","year":"2009","journal-title":"Leukemia Research"},{"issue":"2","key":"10.1002\/14651858.CD003407.pub5-BIB0462|cit462","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1365-2141.2011.08569.x","article-title":"Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: Analysis of the VISTA trial","volume":"153","author":"Richardson","year":"2011","journal-title":"British Journal of Haematology"},{"issue":"6","key":"10.1002\/14651858.CD003407.pub5-BIB0463|cit463","doi-asserted-by":"crossref","first-page":"536","DOI":"10.6004\/jnccn.2008.0042","article-title":"Cancer- and chemotherapy-induced anemia","volume":"6","author":"Rodgers","year":"2008","journal-title":"Journal of the National Comprehensive Network"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0464|cit464","doi-asserted-by":"crossref","unstructured":"Sakai H Saijo N Ohashi Y Once-weekly epoetin beta improves hemoglobin levels and quality of life in patients with chemotherapy-induced anemia:A randomized, double blind, parallel group dose finding study Annals of Oncology 2004","DOI":"10.1200\/jco.2004.22.14_suppl.8169"},{"issue":"Suppl","key":"10.1002\/14651858.CD003407.pub5-BIB0465|cit465","doi-asserted-by":"crossref","first-page":"abstract 8169","DOI":"10.1200\/jco.2004.22.90140.8169","article-title":"Once-weekly epoetin beta improves hemoglobin levels and quality of life in patients with chemotherapy-induced anemia:A randomized, double blind, parallel group dose finding study","volume":"22","author":"Sakai","year":"2004","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD003407.pub5-BIB0466|cit466","first-page":"40","article-title":"Treatment of anemia in patients under radiotherapy with subcutaneous epoetenium alpha 10,000 iu three times a week and 40,000 iu once a week. [Spanish]","volume":"25","author":"Samper","year":"2002","journal-title":"Oncologia (Madrid)"},{"issue":"6","key":"10.1002\/14651858.CD003407.pub5-BIB0467|cit467","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1634\/theoncologist.9-6-696","article-title":"A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer","volume":"9","author":"Schwartzberg","year":"2004","journal-title":"The Oncologist"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD003407.pub5-BIB0468|cit468","first-page":"30","article-title":"Comparable efficacy and safety of darbepoetin alfa 200 mug every 2 weeks and epoetin alfa 40,000 U weekly in patients with breast cancer: Results of a randomized comparison","volume":"3","author":"Schwartzberg","year":"2005","journal-title":"The Journal of Supportive Oncology"},{"issue":"4 Suppl 2","key":"10.1002\/14651858.CD003407.pub5-BIB0469|cit469","first-page":"22","article-title":"A phase II, randomized, open-label study to assess the efficacy of extended-dose schedule administration of darbepoetin alfa in cancer patients with chemotherapy-induced anemia","volume":"5","author":"Schwartzberg","year":"2007","journal-title":"Journal of Supportive Oncology"},{"issue":"7 Pt 1","key":"10.1002\/14651858.CD003407.pub5-BIB0470|cit470","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1097\/00005537-200207000-00015","article-title":"The effects of epoetin alfa on transfusion requirements in head and neck cancer patients: a prospective, randomized, placebo-controlled study","volume":"112","author":"Scott","year":"2002","journal-title":"Laryngoscope"},{"issue":"5","key":"10.1002\/14651858.CD003407.pub5-BIB0471|cit471","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3816\/CBC.2005.n.050","article-title":"Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly","volume":"6","author":"Senecal","year":"2005","journal-title":"Clinical Breast Cancer"},{"issue":"5","key":"10.1002\/14651858.CD003407.pub5-BIB0472|cit472","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/cncr.11616","article-title":"Once-weekly dosing of epoetin-alpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy","volume":"98","author":"Shasha","year":"2003","journal-title":"Cancer"},{"issue":"2","key":"10.1002\/14651858.CD003407.pub5-BIB0473|cit473","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1586\/14737167.7.2.187","article-title":"Impact of dose frequency on compliance and health outcomes: A literature review (1966-2006)","volume":"7","author":"Shi","year":"2007","journal-title":"Expert Review of Pharmacoeconomics and Outcomes Research"},{"issue":"6","key":"10.1002\/14651858.CD003407.pub5-BIB0474|cit474","first-page":"279","article-title":"Treating chemotherapy-induced anemia following the revised labeling for ESAs","volume":"6","author":"Shord","year":"2009","journal-title":"Community"},{"issue":"8","key":"10.1002\/14651858.CD003407.pub5-BIB0475|cit475","first-page":"969","article-title":"[Epoetin beta for the treatment of chemotherapy-induced anaemia in solid and haematological malignancies. Results of an open-label, multicentric clinical trial]","volume":"97","author":"Spaeth","year":"2010","journal-title":"Bulletin du cancer"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0476|cit476","unstructured":"Spicka I Beguin Y Effect of anemia correction with epoetin beta (neorecormon) once weekly on performance status and disease response Hematology Journal 2004 abstract 553"},{"issue":"7","key":"10.1002\/14651858.CD003407.pub5-BIB0477|cit477","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1200\/JCO.2005.02.7276","article-title":"Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancer","volume":"24","author":"Steensma","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0478|cit478","doi-asserted-by":"crossref","unstructured":"Steensma DP Molina R Sloan JA Nikcevich DA Schaefer Pl Rowland KM A phase III randomized trial of two different dosing schedules of erythropoietin (EPO) in patients with cancer-associated anemia: North Central Cancer Treatment Group (NCCTG) study N02C2 Journal of Clinical Oncology abstract 8031","DOI":"10.1200\/jco.2005.23.16_suppl.8031"},{"issue":"1","key":"10.1002\/14651858.CD003407.pub5-BIB0479|cit479","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1200\/JCO.2010.30.3644","article-title":"Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia","volume":"29","author":"Steensma","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10.1002\/14651858.CD003407.pub5-BIB0480|cit480","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1182\/blood.V78.7.1658.1658","article-title":"Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes","volume":"78","author":"Stein","year":"1991","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD003407.pub5-BIB0481|cit481","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00520-010-0812-2","article-title":"A new concept for the differential diagnosis and therapy of anaemia in cancer patients","volume":"19","author":"Steinmetz","year":"2011","journal-title":"Supportive Care in Cancer"},{"issue":"2","key":"10.1002\/14651858.CD003407.pub5-BIB0482|cit482","first-page":"83","article-title":"Adapting practice in the face of new data","volume":"5","author":"Stokoe","year":"2009","journal-title":"Journal of Practice"},{"issue":"8","key":"10.1002\/14651858.CD003407.pub5-BIB0483|cit483","first-page":"1097","article-title":"Cancer-related fatigue","volume":"44","author":"Stone","year":"2008","journal-title":"European Journal of"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0484|cit484","unstructured":"Straus DJ Turner RR Testa MA Hayes JF Sarokhan BJ Epoetin Alfa treatment Improves Quality of Life and Increases Hemoglobin Levels during Chemotherapy for Lymphoma, Chronic Lymphocytic Leukemia (CLL)., and Multiple Myeloma (MM) Patients with Mild-to-Moderate Anemia Blood, ASH Annual Meeting 2002"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0485|cit485","unstructured":"Straus DJ Testa M Riggs SA Tulpule A Sarokhan B Early treatment with epoetin alfa improves anemia, quality of life, and productivity in patients with hematologic malignancies and mild anemia during chemotherapy Blood 2003 abstract 1811"},{"issue":"8","key":"10.1002\/14651858.CD003407.pub5-BIB0486|cit486","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1002\/cncr.22221","article-title":"Quality-of-life and health benefits of early treatment of mild anemia: a randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies","volume":"107","author":"Straus","year":"2006","journal-title":"Cancer"},{"issue":"2","key":"10.1002\/14651858.CD003407.pub5-BIB0487|cit487","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.cct.2009.12.006","article-title":"Use of latent growth curve models for assessing the effects of darbepoetin alfa on hemoglobin and fatigue","volume":"31","author":"Stull","year":"2010","journal-title":"Contemporary Clinical Trials"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0488|cit488","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/jjco\/hyn002","article-title":"Weekly epoetin beta maintains haemoglobin levels and improves quality of life in patients with non-myeloid malignancies receiving chemotherapy","volume":"38","author":"Suzuki","year":"2008","journal-title":"Japanese Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0489|cit489","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1023\/A:1007951530405","article-title":"Effectiveness of weekly subcutaneous recombinant human erythropoietin administration for chemotherapy-induced anemia","volume":"11","author":"Tsukuda","year":"1998","journal-title":"Biotherapy"},{"issue":"7","key":"10.1002\/14651858.CD003407.pub5-BIB0490|cit490","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1185\/03007990903050876","article-title":"Therapeutic effects of epoetin zeta in the treatment of chemotherapy-induced anaemia","volume":"25","author":"Tzekova","year":"2009","journal-title":"Current Medical Research & Opinion"},{"issue":"50","key":"10.1002\/14651858.CD003407.pub5-BIB0491|cit491","first-page":"32","article-title":"Cancer and chemotherapy associated anemia: Do erythropoietins worsen the prognosis?","volume":"147","author":"Uhl","year":"2007","journal-title":"Deutsche Apotheker Zeitung"},{"issue":"2","key":"10.1002\/14651858.CD003407.pub5-BIB0492|cit492","first-page":"131","article-title":"Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks","volume":"1","author":"Vadhan-Raj","year":"2003","journal-title":"Journal of Supportive Oncology"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0493|cit493","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0494|cit494","unstructured":"Johnson & Johnson Pharmaceutical Research & Development L.L.C Background information for Oncologic Drugs Advisory Committee Meeting, Safety of Erythropoietin Receptor Agonists (ERAs) in Patients With Cancer Johnson and Johnson briefing document for FDA\/ODAC hearing May 4, 2004; Gaithersburg, MD,"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0495|cit495","unstructured":"Luksenburg H Weir A Wager R EPO-GBR-7: Safety Concerns Associated with Aranesp (darbepoetin alfa) Amgen Inc. and Procrit (epoetin alfa) Ortho Biotech L.P., for the Treatment of Anemia Associated with Cancer Chemotherapy Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Oncologic Drugs Advisory Committee, Rockville (MD), USA, 2004"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0496|cit496","doi-asserted-by":"crossref","unstructured":"Vadhan-Raj S Skibber JM Crane C Buesos-Ramos CE Rodriguez-Bigas MA Feig BW Randomized, double-blind, placebo-controlled trial of epoetin alfa (Procrit) in patients with rectal and gastric cancer undergoing chemo-radiotherapy (CT\/RT) followed by surgery: early termination of the trial due to increased incidence of thrombo-embolic events (TEE) Blood 2004 #2915","DOI":"10.1182\/blood.V104.11.2915.2915"},{"issue":"4","key":"10.1002\/14651858.CD003407.pub5-BIB0497|cit497","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/mpo.10185","article-title":"Is epoetin alfa a treatment option for chemotherapy-related anemia in children?","volume":"39","author":"Buyukpamukcu","year":"2002","journal-title":"Medical and Pediatric Oncology"},{"issue":"2","key":"10.1002\/14651858.CD003407.pub5-BIB0498|cit498","doi-asserted-by":"crossref","first-page":"E161","DOI":"10.1542\/peds.103.2.e16","article-title":"Recombinant human erythropoietin treatment for chemotherapy-related anemia in children","volume":"103","author":"Varan","year":"1999","journal-title":"Pediatrics"},{"issue":"5","key":"10.1002\/14651858.CD003407.pub5-BIB0499|cit499","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/j.1537-2995.2008.02072.x","article-title":"Impact of limiting erythropoiesis-stimulating agent use for chemotherapy-induced anemia on the United States blood supply margin.[see comment]","volume":"49","author":"Vekeman","year":"2009","journal-title":"Transfusion"},{"issue":"8","key":"10.1002\/14651858.CD003407.pub5-BIB0500|cit500","first-page":"45","article-title":"Effect of two administration schedules of erythropoietin upon hemoglobin in breast cancer patients treated with radiation therapy. [Spanish]","volume":"26","author":"Velilla Millan","year":"2003","journal-title":"Oncologia (Madrid)"},{"issue":"0125-2208 (Prin","key":"10.1002\/14651858.CD003407.pub5-BIB0501|cit501","first-page":"1082","article-title":"Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy","volume":"90","author":"Voravud","year":"2007","journal-title":"Journal of the Meical Association of Thailand"},{"issue":"10","key":"10.1002\/14651858.CD003407.pub5-BIB0502|cit502","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1200\/JCO.2004.01.002","article-title":"Combined use of erythropoietin and granulocyte colony- stimulating factor does not decrease blood transfusion requirements during induction therapy for high-risk neuroblastoma: A randomized controlled trial","volume":"22","author":"Wagner","year":"2004","journal-title":"Journal of Clinical Oncology"},{"issue":"7772","key":"10.1002\/14651858.CD003407.pub5-BIB0503|cit503","first-page":"547","article-title":"Managing anaemia in critically ill adults","volume":"341","author":"Walsh","year":"2010","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0504|cit504","doi-asserted-by":"crossref","unstructured":"Waltzman R WD Head-to-head comparison of epoetin alfa (EPO) 40,000 QW vs darbepoetin alfa (DARB) 200 \u00b5g Q2W in anemic cancer patients receiving chemotherapy (CT): final results of a planned interim analysis (IA) Blood 2004","DOI":"10.1182\/blood.V104.11.4233.4233"},{"issue":"7","key":"10.1002\/14651858.CD003407.pub5-BIB0505|cit505","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1002\/cncr.20116","article-title":"A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease","volume":"100","author":"Waltzman","year":"2004","journal-title":"Cancer"},{"issue":"8","key":"10.1002\/14651858.CD003407.pub5-BIB0506|cit506","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1634\/theoncologist.10-8-642","article-title":"Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 microg every 2 weeks) in anemic patients with cancer receiving chemotherapy","volume":"10","author":"Waltzman","year":"2005","journal-title":"The Oncologist"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0507|cit507","doi-asserted-by":"crossref","unstructured":"Waltzman RJ Croot C Williams D Final haematologic results: epoetin alfa (EPO) 40,000 U QW vs darbepoetin alfa (DARB) 200 \u00b5g Q2W in anemic cancer patients (pts) receiving chemotherapy (CT) Journal of Clinical Oncology 2005 abstract 8030","DOI":"10.1200\/jco.2005.23.16_suppl.8030"},{"issue":"2","key":"10.1002\/14651858.CD003407.pub5-BIB0508|cit508","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2147\/tcrm.2006.2.2.175","article-title":"Flexible dosing with Darbepoetin alfa for the treatment of chemotherapy-induced anemia","volume":"2","author":"Wauters","year":"2006","journal-title":"Therapeutics & Clinical Risk Management"},{"issue":"2","key":"10.1002\/14651858.CD003407.pub5-BIB0509|cit509","first-page":"125","article-title":"Regulatory Action and News: Erythropoietin: withdrawal of marketing authorization application","volume":"25","author":"WHO","year":"2011","journal-title":"WHO Drug Information"},{"issue":"2","key":"10.1002\/14651858.CD003407.pub5-BIB0510|cit510","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s12185-008-0130-3","article-title":"A multi-center open-labeled study of recombinant erythropoietin-(beta) in the treatment of anemic patients with multiple myeloma, low-grade non-Hodgkin's lymphoma, or chronic lymphocytic leukemia in Chinese population","volume":"88","author":"Yang","year":"2008","journal-title":"International Journal of Hematology"},{"issue":"1","key":"10.1002\/14651858.CD003407.pub5-BIB0511|cit511","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/pho.21.1.1.8","article-title":"A single institutional experience: Is epoetin alpha effective in anemic children with cancer?","volume":"21","author":"Yilmaz","year":"2004","journal-title":"Pediatric Hematology & Oncology"},{"issue":"4","key":"10.1002\/14651858.CD003407.pub5-BIB0512|cit512","first-page":"199","article-title":"Treatment of anemia by recombinant human erythropoietin in cancer patients undergoing radiotherapy","volume":"4","author":"Yurut-Caloglu","year":"2008","journal-title":"Asia-Pacific Journal of Clinical"},{"issue":"4 Suppl 2","key":"10.1002\/14651858.CD003407.pub5-BIB0513|cit513","first-page":"abstract 0177","article-title":"An open-label, controlled, randomized, dose comparison study of epoetin alfa for the treatment of anemia in cancer patients receiving platinum-containing chemotherapy","volume":"61","author":"Zagari","year":"2003","journal-title":"The Hematology Journal"},{"issue":"1","key":"10.1002\/14651858.CD003407.pub5-BIB0514|cit514","first-page":"35","article-title":"Improvement of anemia and quality of life of patients with prostate cancer by treatment with human recombinant erythropoietin","volume":"57","author":"Queipo Zaragoza","year":"2004","journal-title":"Archivos espa\u00f1oles de urolog\u00eda"},{"issue":"8","key":"10.1002\/14651858.CD003407.pub5-BIB0515|cit515","first-page":"861","article-title":"Clinical observations on RHuEPO in the treatment of breast cancer chemotherapy related anemia","volume":"10","author":"Zhang","year":"2003","journal-title":"China Journal of Cancer Prevention and Treatment"},{"issue":"5","key":"10.1002\/14651858.CD003407.pub5-BIB0516|cit516","first-page":"355","article-title":"Clinical observation of recombinant human erythropoietin in treatment of preoperative anemia in patients with gastric cancer","volume":"6","author":"Zhou","year":"2006","journal-title":"Pharmaceutical Care & Research (Yaoxue Fuwu Yu Yanjiu)"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0517|cit517","unstructured":"Blackstock AW A phase III randomised trial evaluating the effect of e\u00fcpetin alfa (procrit) on local control in patietns undergoing cocnurrent chemotherapy and radiation therapy for non-small cell lung cancer. NCT00028938 ClinicalTrials.gov last updated August 2009"},{"issue":"21","key":"10.1002\/14651858.CD003407.pub5-BIB0518|cit518","first-page":"1880","article-title":"Interim Results of A Randomized Phase II Trial of Azacitidine (AZA) +\/- Epo In Lower Risk Myelodysplastic Syndrome (MDS) Resistant to An Erythropoietic Stimulating Agent (ESA) Alone","volume":"116","author":"Boehrer","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0519|cit519","unstructured":"Broadley K Double blind randomised placebo controlled trial of the effect of epoetin alfa on symptomatic anaemia and fatigue in cancer patients receiving ongoing care without planned chemotherapy. N0258040123 National Research Register 2003"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0520|cit520","unstructured":"Chapman CS A randomised comparison of the effect of maintaining haemoglobin levels with weekly epoetin alfa or with conventional anaemia management in subjects with multiple myeloma undergoing chemotherapy (EMMY). N0123138194 NRR 2004"},{"issue":"22","key":"10.1002\/14651858.CD003407.pub5-BIB0521|cit521","doi-asserted-by":"crossref","first-page":"Abstract 1701","DOI":"10.1182\/blood.V114.22.1701.1701","article-title":"Efficacy and safety of prophylactic use of darbepoetin alfa in patients with diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: results of the interim analysis of the LNH03-6B GELA Study","volume":"114","author":"Delarue","year":"2009","journal-title":"Blood"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0522|cit522","unstructured":"EPO-CAN-303 Treatment of anaemic patients with cancer who are not receiving chemotherapy or radiotherapy ClinicalTrials.gov Last updated 2007"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0523|cit523","doi-asserted-by":"crossref","unstructured":"Famoyin C Byrnes C Roberts S Gollob M Atkins M Mier J A randomized phase II study of thalidomide with or without erythropoietin (EPO) in metastatic renal cell carcinoma (RCC) Journal of Clinical Oncology 2004","DOI":"10.1200\/jco.2004.22.90140.4747"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0524|cit524","unstructured":"Fisch MJ Epoetin Alfa in treating fatigue in patients with advanced solid tumors who are not receiving chemotherapy. NCT00052221 ClinicalTrials.gov Last updated 2009"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0525|cit525","unstructured":"Gallagher C The role of epoetin alpha in anaemia and fatigue in cancer patients. N0205036683 National Research Register 2003"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0526|cit526","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0959-8049(05)80283-7","article-title":"Erythropoietin for the prevention of anaemia in neoplastic patients treated with cisplatin","volume":"29A Suppl 2","author":"Gamucci","year":"1993","journal-title":"European Journal of Cancer"},{"issue":"15","key":"10.1002\/14651858.CD003407.pub5-BIB0527|cit527","doi-asserted-by":"crossref","first-page":"Abstract TPS325","DOI":"10.1200\/jco.2010.28.15_suppl.tps325","article-title":"Design of an ongoing randomized study on the long-term safety and efficacy of darbepoetin alfa (DA) administered 500 mcg every three weeks (Q3W) to non-small cell lung cancer (NSCLC) patients (pts) with anemia concomitant with chemotherapy (ACC)","volume":"28","author":"Gascon","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0528|cit528","unstructured":"Ghavamzadeh A Alimoghaddam K Jahani M Hamidieh AA Mousavi SA Khatami F Randomized, double blind, placebo-controlled phase III study of weekly administration of darbepoetin alfa in anemic patients with lung or gynecologic cancer receiving platinum-containing chemotherapy ABMT 2010 Annual Meeting. 2010"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0529|cit529","unstructured":"Howell A A double-blind, randomised, placebo-controlled study to evaluate the impact of maintaining haemoglobin using Epres R (epoetin alpha) in stage IV breast cancer sugjects receiving chemotherapy. N0063096721 National Research Register 2003"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0530|cit530","unstructured":"H Thomas Open label comparative evaluation of the effect of epoetin on quality of life and burden of illness in anaemic patients receiving platinum-containing chemotherapy Cochrane Review 1997"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0531|cit531","unstructured":"Koelbl H Epoetin beta in treating anemia in patients with cervical cancer. NCT00046969 ClinicalTrials.gov Last updated 2009"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0532|cit532","unstructured":"Lambin P Radiation therapy with or without epoetin alfa in treating patients with head and neck cancer. NCT00017277 ClinicalTrials.gov Last updated 2009"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0533|cit533","first-page":"58","article-title":"The clinical study on recombinant human erythropoietin for chemotherapy - related anaemia","volume":"29(1)","author":"Liang","year":"2009","journal-title":"Clinical Research"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0534|cit534","doi-asserted-by":"crossref","unstructured":"Nitz U Oberhoff C Reimer T Schumacher C Hackmann J Warm M et al. West German Study Group Moenchengladbach Germany Marienhospital Essen Germany Klinikum Suedstadt Rostock Germany St. Elisabeth KH Koeln Germany Uni Koeln Koeln Germany HZM Pharmaservice Wiesbaden Germany Praxis Gyn. Onko Hildesheim Germany Wilhelm-Anton-H Goch Germany Adjuvant chemotherapy with or without darbepoetin in node-positive breast cancer: a safety analysis from the phase III ARA plus trial. San Antonio Breast Cancer Symposium 2008 4100","DOI":"10.1158\/0008-5472.SABCS-4100"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0535|cit535","unstructured":"O'Brien Open-label randomised group-comparative evaluation of the effect of epoetin on anaemia and fatigue in lung cancer patients receiving palliative platinumcontaining chemotherapy Cochrane Review 1998"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0536|cit536","unstructured":"O'Connell MJ Phase III Randomised study of epoetin alpha in anemic patients with advanced cancer undergoing chemotherapy.NCCTG-979253\/ NCT00003600 Cancer.gov, ClinicalTrials.gov Last updated 2009"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD003407.pub5-BIB0537|cit537","first-page":"63","article-title":"Clinical evaluation of recombinant human erythropoietin(Eprex r) in anemic cancer patients receiving chemotherapy","volume":"7","author":"Park","year":"1996","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0538|cit538","unstructured":"Parliament M Phase III randomised study of radiotherapy with or without epoetin alfa in anemic patients with squamous cell carcinoma of the head and neck ClinicalTrials.gov"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0539|cit539","unstructured":"Recasens V Rubio-Martinez A Gomez-Barrera M Rubio-Felix D Giralt M Giraldo P A pharmacoeconomical analysis comparing Epoetin Alpha vs transfusion in patients with anemia associated to multiple myeloma Blood 2003"},{"issue":"S1","key":"10.1002\/14651858.CD003407.pub5-BIB0540|cit540","first-page":"S202","article-title":"Anemia associated to multiple myeloma: repsonse to epoetin alpha","volume":"4","author":"Rubio-Martinez","year":"2003","journal-title":"Hematology Journal"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0541|cit541","doi-asserted-by":"crossref","unstructured":"Rexer H Urologe;45:1017-1018 2006","DOI":"10.1007\/s00120-006-1154-z"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0542|cit542","unstructured":"R Thomas Open-label comparative group evaluation of the effect of epoetin alfa on quality of life and burden of illness in anaemic cancer patients receiving platinum containing chemotherapy. N0040004850 Current cotrolled trials 2002"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0543|cit543","unstructured":"Rudd M Evaluation of epoetin alpha in lung cancer patients receiving chemotherapy. N0205036678 Current Controlled Trials 2002"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0544|cit544","unstructured":"Stewart JSW Open randomised comperative group evaluation of the effect of epoetin alfa on local disease free survival and quality of life in head and neck cancer patients receiving radical radiotherapy. N0016089950 Current Controolled Trials 2002"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0545|cit545","unstructured":"UKCCCR GN308 A double-blind, placebo-controlled study to assess the effects of early intervention and\/or treatment with epoetin alfa on anaemia in cancer patients receiving non-platinum containing chemotherapy ISRCTN Register 2009"},{"issue":"21","key":"10.1002\/14651858.CD003407.pub5-BIB0546|cit546","first-page":"2092","article-title":"The effectiveness of a fixed low dose of erythropoietin (EPO) in anemic solid tumor patients receiving concomitant chemotherapy: a prospective, randomized, controlled study","volume":"118","author":"Youssef Lama","year":"2011","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0547|cit547","first-page":"Abstract #2987","article-title":"Soluble transferrin receptor (sTFR) as a predictor of response to prophylactic epoetin alfa (EPO) treatment in non-anemic cancer patients (pts) under chemotherapy (CT). Preliminary results","volume":"20","author":"Ziras","year":"2001","journal-title":"Proceedings of the American Society of Clincal Oncology"},{"issue":"11","key":"10.1002\/14651858.CD003407.pub5-BIB0548|cit548","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.bjc.6603481","article-title":"Effect of treatment with epoetin beta on short-term tumour progression and survival in anaemic patients with cancer: A meta-analysis","volume":"95","author":"Aapro","year":"2006","journal-title":"British Journal of Cancer"},{"issue":"17","key":"10.1002\/14651858.CD003407.pub5-BIB0549|cit549","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1016\/j.ejca.2009.06.031","article-title":"What is the impact of antithrombotic therapy and risk factors on the frequency of thrombovascular events in patients with metastatic breast cancer receiving epoetin beta?","volume":"45","author":"Aapro","year":"2009","journal-title":"European Journal of Cancer (Oxford, England : 1990)"},{"issue":"12","key":"10.1002\/14651858.CD003407.pub5-BIB0550|cit550","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1038\/sj.bjc.6605255","article-title":"Epoetin-beta treatment in patients with cancer chemotherapy-induced anaemia: the impact of initial haemoglobin and target haemoglobin levels on survival, tumour progression and thromboembolic events","volume":"101","author":"Aapro","year":"2009","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0551|cit551","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/1097-0142(19910201)67:3+<844::AID-CNCR2820671416>3.0.CO;2-B","article-title":"Methodologic issues in assessing the quality of life in cancer patients","volume":"67","author":"Aaronson","year":"1991","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0552|cit552","first-page":"3561","article-title":"Erythropoietin and erythropietin receptor expression in human cancer","volume":"61","author":"Acs","year":"2001","journal-title":"Cancer Research"},{"issue":"5","key":"10.1002\/14651858.CD003407.pub5-BIB0553|cit553","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1002\/cncr.10787","article-title":"Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma","volume":"95","author":"Acs","year":"2002","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0554|cit554","article-title":"Assessment of study quality","volume-title":"Cochrane Reviewers' Handbook 4.2.2 [updated March 2004]","author":"Alderson","year":"2005"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0555|cit555","unstructured":"Amgen Inc Aranesp (darbepoetin alfa) Safety Oncologic Drugs Advisory Committee; 4 May 2004"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0556|cit556","unstructured":"Amgen Thousand Oaks Safety of Erythropoiesis-Stimulating Agents (ESAs) in Oncology 2007 ODAC Meeting Information Package Darbepoetin alfa and Epoetin alfa; BACKGROUND INFORMATIONFORONCOLOGIC DRUGS ADVISORY COMMITTEE"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0557|cit557","unstructured":"Amgen in collaboration with Johnson & Johnson ODAC Meeting Briefing Document Epoetin alfa (Epogen\u00ae\/PROCRIT\u00ae) and darbepoetin alfa (Aranesp\u00ae) http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/08\/briefing\/2008-4345b2-00-FDA-index.htm"},{"issue":"7","key":"10.1002\/14651858.CD003407.pub5-BIB0558|cit558","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/01.LAB.0000020415.72863.40","article-title":"Functional significance of erythropoietin receptor expression in breast cancer","volume":"82","author":"Arcasoy","year":"2002","journal-title":"Laboratory Investigation"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0559|cit559","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.radonc.2010.02.008","article-title":"Erythropoiesis stimulating agents, thrombosis and cancer","volume":"95","author":"Barbera","year":"2010","journal-title":"Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology"},{"issue":"2","key":"10.1002\/14651858.CD003407.pub5-BIB0560|cit560","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0360-3016(99)00384-3","article-title":"Severe anemia is associated with poor tumor oxygenation in head and neck squamous cell carcinomas","volume":"46","author":"Becker","year":"2000","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"4","key":"10.1002\/14651858.CD003407.pub5-BIB0561|cit561","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2165\/00002018-199819040-00003","article-title":"A Risk-benefit assessment of epoetin in the management of anaemia associated with cancer","volume":"19","author":"Beguin","year":"1998","journal-title":"Drug Safety"},{"issue":"8","key":"10.1002\/14651858.CD003407.pub5-BIB0562|cit562","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/jama.299.8.914","article-title":"Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia","volume":"299","author":"Bennett","year":"2008","journal-title":"JAMA"},{"issue":"16","key":"10.1002\/14651858.CD003407.pub5-BIB0563|cit563","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1001\/archinternmed.2010.309","article-title":"Association between pharmaceutical support and basic science research on erythropoiesis-stimulating agents","volume":"170","author":"Bennett","year":"2010","journal-title":"Archives of Internal Medicine"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0564|cit564","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9674","key":"10.1002\/14651858.CD003407.pub5-BIB0565|cit565","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/S0140-6736(09)60502-X","article-title":"Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials","volume":"373","author":"Bohlius","year":"2009","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0566|cit566","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S1470-2045(02)00677-0","article-title":"Human recombinant erythropoietin and quality of life: a wonder drug or something to wonder about?","volume":"3","author":"Bottomley","year":"2002","journal-title":"Lancet Oncology"},{"issue":"Suppl. 1","key":"10.1002\/14651858.CD003407.pub5-BIB0567|cit567","first-page":"S23","article-title":"Assessing the impact of cancer-related anaemia on quality of life and the role of rHuEPO","volume":"17","author":"Brandberg","year":"2000","journal-title":"Medical Oncology"},{"issue":"12","key":"10.1002\/14651858.CD003407.pub5-BIB0568|cit568","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1002\/1097-0142(20010615)91:12<2214::AID-CNCR1251>3.0.CO;2-P","article-title":"Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review","volume":"91","author":"Caro","year":"2001","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0569|cit569","first-page":"N\/A","article-title":"Red blood cell transfusion: a clinical practice guideline from the AABB","volume":"Published onlin","author":"Carson","journal-title":"Annals of Internal Medicine"},{"issue":"3 Suppl 2","key":"10.1002\/14651858.CD003407.pub5-BIB0570|cit570","first-page":"13","article-title":"The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue","volume":"34","author":"Cella","year":"1997","journal-title":"Seminars in Hematology"},{"issue":"3 Suppl 7","key":"10.1002\/14651858.CD003407.pub5-BIB0571|cit571","first-page":"43","article-title":"Factors influencing quality of life in cancer patients: anemia and fatigue","volume":"25","author":"Cella","year":"1998","journal-title":"Seminars in Oncology"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0572|cit572","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1046\/j.1523-5394.1999.74008.x","article-title":"The effect of epoetin alfa on quality of life in anemic cancer patients","volume":"7","author":"Cella","year":"1999","journal-title":"Cancer Practice"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0573|cit573","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0885-3924(02)00529-8","article-title":"Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales","volume":"24","author":"Cella","year":"2002","journal-title":"Journal of Pain and Symptom Mmanagement"},{"issue":"6","key":"10.1002\/14651858.CD003407.pub5-BIB0574|cit574","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/annonc\/mdh235","article-title":"The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials","volume":"15","author":"Cella","year":"2004","journal-title":"Annals of Oncology : official journal of the European Society for Medical Oncology \/ ESMO"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0575|cit575","unstructured":"Cella D The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale: Summary of development and validation Elmhurst, IL, FACIT.org 2007"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0576|cit576","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1159\/000187555","article-title":"Relationship between hematocrit and blood pressure: implications for primary hypertension","volume":"65","author":"Cirillo","year":"1993","journal-title":"Nephron"},{"issue":"1","key":"10.1002\/14651858.CD003407.pub5-BIB0577|cit577","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1471-2407-2-23","article-title":"Erythropoietin, uncertainty principle and cancer related anaemia","volume":"2","author":"Clark","year":"2002","journal-title":"BMC Cancer"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0578|cit578","unstructured":"Dalton JD Bailey NP Barrett-Lee PJ O\u00b4Brien MER Multicenter UK audit of anemia in patients receiving cytotoxic chemotherapy American Society of Clinical Oncology 1998 Abstract #1611"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0579|cit579","doi-asserted-by":"crossref","unstructured":"Deeks J Are you sure that's a standard deviation? Cochrane News 1997 11 2","DOI":"10.7748\/ns.11.25.11.s26"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0580|cit580","unstructured":"Deeks JJ Higgins JPT Altman DG Chapter 9: Analysing data and undertaking meta-analyses. Higgins JPT, Green S, editor(s). Cochrane Handbook of Systematic Reviews of Interventions, version 5.1.0 (updated March 2011) 2011"},{"issue":"1","key":"10.1002\/14651858.CD003407.pub5-BIB0581|cit581","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007148.pub2","article-title":"Pre and peri-operative erythropoeitin for reducing allogeneic blood transfusions in colorectal cancer surgery","author":"Devon","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0582|cit582","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0092-8674(89)90965-3","article-title":"Expression cloning of the murine erythropoietin receptor","volume":"57","author":"D\u00b4Andrea","year":"1989","journal-title":"Cell"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0583|cit583","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"5","key":"10.1002\/14651858.CD003407.pub5-BIB0584|cit584","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2165\/00115677-200008050-00002","article-title":"Recombinant human erythropoietin as an alternative to blood transfusion in cancer-related anaemia","volume":"8","author":"Engert","year":"2000","journal-title":"Disease Management and Clinical Outcomes"},{"issue":"8","key":"10.1002\/14651858.CD003407.pub5-BIB0585|cit585","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1023\/A:1026116426494","article-title":"Evaluation of quality of life in a clinical trial with nonrandom dropout: the effect of epoetin alfa in anemic cancer patients","volume":"12","author":"Fairclough","year":"2003","journal-title":"Quality of Life Research"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0586|cit586","unstructured":"FDA Drug Safety Communication: Erythropoiesis-Stimulating Agents (ESAs): Procrit, Epogen and Aranesp http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm200297.htm"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0587|cit587","unstructured":"FDA Continuing Reassessment of the Risks of Erythropoiesis-Stimulating Agents (ESAs) Administered for the Treatment of Anemia associated with Cancer Chemotherapy FDA BRIEFING DOCUMENT May 10, 2007 Oncologic Drugs Advisory Committee"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0588|cit588","unstructured":"FDA BRIEFING DOCUMENT March 13, 2008, Oncologic Drugs Advisory Committee http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/08\/briefing\/2008-4345b2-00-FDA-index.htm"},{"issue":"Suppl IV","key":"10.1002\/14651858.CD003407.pub5-BIB0589|cit589","first-page":"31","article-title":"The impact of blood hemoglobin content on the outcome of radiotherapy. The Freiburg experience","volume":"174","author":"Frommhold","year":"1998","journal-title":"Strahlentherapie und Onkologie"},{"issue":"4","key":"10.1002\/14651858.CD003407.pub5-BIB0590|cit590","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1055\/s-0037-1613275","article-title":"Erythropoietin triggers a signaling pathway in endothelial cells and increases the thrombogenicity of their extracellular matrices in vitro","volume":"88","author":"Fuste","year":"2002","journal-title":"Thrombosis and haemostasis"},{"issue":"17","key":"10.1002\/14651858.CD003407.pub5-BIB0591|cit591","doi-asserted-by":"crossref","first-page":"4425","DOI":"10.1182\/blood-2011-01-258467","article-title":"Hepcidin and iron regulation, 10 years later","volume":"117","author":"Ganz","year":"2011","journal-title":"Blood"},{"issue":"10","key":"10.1002\/14651858.CD003407.pub5-BIB0592|cit592","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1093\/annonc\/mdq073","article-title":"Effects of CERA (continuous erythropoietin receptor activator) in patients with advanced non-small-cell lung cancer (NSCLC) receiving chemotherapy: results of a phase II study","volume":"21","author":"Gascon","year":"2010","journal-title":"Annals of Oncology : official journal of the European Society for Medical Oncology \/ ESMO"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0593|cit593","first-page":"20","article-title":"The impact of epoetin alfa on quality of life during cancer chemotherapy: a fresh look at an old problem","volume":"34 Suppl 2","author":"Glaspy","year":"1997","journal-title":"Seminars in Hematology"},{"issue":"2","key":"10.1002\/14651858.CD003407.pub5-BIB0594|cit594","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/sj.bjc.6605498","article-title":"Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes","volume":"102","author":"Glaspy","year":"2010","journal-title":"British Journal of Cancer"},{"issue":"7","key":"10.1002\/14651858.CD003407.pub5-BIB0595|cit595","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1056\/NEJM199902183400706","article-title":"Transfusion medicine - blood transfusion - second of two parts","volume":"340","author":"Goodnough","year":"1999","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0596|cit596","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/978-3-642-58813-6_10","article-title":"Significance of hemoglobin concentration for treatment outcome","volume-title":"Blood Perfusion and Microenvironment of Human Tumors","author":"Grau","year":"2000"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0597|cit597","first-page":"1098","article-title":"The myelodysplastic syndromes","volume-title":"Hematology: Basic Principles and Practice","author":"Greenberg","year":"1994"},{"issue":"19","key":"10.1002\/14651858.CD003407.pub5-BIB0598|cit598","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/jnci\/91.19.1616","article-title":"Chemotherapy-Induced Anemia in Adults: Incidence and Treatment","volume":"91","author":"Groopman","year":"1999","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0599|cit599","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/clpt.1991.210","article-title":"Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta","volume":"50","author":"Halstenson","year":"1991","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"2 Suppl 8","key":"10.1002\/14651858.CD003407.pub5-BIB0600|cit600","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0093-7754(01)90214-3","article-title":"Prevalence of anemia in cancer patients undergoing radiation therapy","volume":"28","author":"Harrison","year":"2001","journal-title":"Seminars in Oncology"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0601|cit601","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease","volume":"339","author":"Hasenclever","year":"1998","journal-title":"New England Journal of Medicine"},{"issue":"28","key":"10.1002\/14651858.CD003407.pub5-BIB0602|cit602","doi-asserted-by":"crossref","first-page":"6941","DOI":"10.1200\/JCO.2005.03.434","article-title":"Darbepoetin alfa for the treatment of chemotherapy-induced anemia: disease progression and survival analysis from four randomized, double-blind, placebo-controlled trials","volume":"23","author":"Hedenus","year":"2005","journal-title":"Journal of Clinical Oncology : official journal of the American Society of Clinical Oncology"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0603|cit603","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1365-2141.1995.tb08909.x","article-title":"Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies","volume":"89","author":"Hellstr\u00f6m-Lindberg","year":"1995","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0604|cit604","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000012096","article-title":"Erythropoietin in radiation oncology - a review","volume":"58","author":"Henke","year":"2000","journal-title":"Oncology"},{"issue":"29","key":"10.1002\/14651858.CD003407.pub5-BIB0605|cit605","doi-asserted-by":"crossref","first-page":"4708","DOI":"10.1200\/JCO.2006.06.2737","article-title":"Do erythropoietin receptors on cancer cells explain unexpected clinical findings?","volume":"24","author":"Henke","year":"2006","journal-title":"Journal of Clinical Oncology : official journal of the American Society of Clinical Oncology"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0606|cit606","first-page":"3","article-title":"Changing patterns of care in the management of anemia","volume":"19","author":"Henry","year":"1992","journal-title":"Seminars in Oncology"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0607|cit607","unstructured":"Higgins JPT Green S Chapter 8: Assessing risk of bias in included studies. Higgins JPT, Green S, editor(s). Cochrane Handbook of Systematic Reviews of Interventions 5.1.0 (updated March 2011) 2011"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0608|cit608","unstructured":"Higgins JPT Deeks JJ Altman DG Chapter 16: Special topics in statistics Higgins JPT, Green S, editor(s). Cochrane Handbook of Systematic Reviews of Intervetions, Version 5.1.0 (updated March 2011) 2011"},{"issue":"4","key":"10.1002\/14651858.CD003407.pub5-BIB0609|cit609","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1080\/09553008414551521","article-title":"The effect of alterations in haematocrit on tumour sensitivity to X-rays","volume":"46","author":"Hirst","year":"1984","journal-title":"International Journal of Radiation Biology and Related Studies in Physics, Chemistry, and Medicine"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0610|cit610","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0167-8140(93)90025-4","article-title":"Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix","volume":"26","author":"Hockel","year":"1993","journal-title":"Radiotherapy Oncology"},{"issue":"1","key":"10.1002\/14651858.CD003407.pub5-BIB0611|cit611","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Medical Research Methodology"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0612|cit612","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/10618600.1996.10474713","article-title":"R: A language for Data Analysis and Graphics","volume":"5","author":"Ihaka","year":"1996","journal-title":"Journal of Computational and Graphical Statistics"},{"issue":"11","key":"10.1002\/14651858.CD003407.pub5-BIB0613|cit613","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00277-004-0911-6","article-title":"Beneficial and ominous aspects of the pleiotropic action of erythropoietin","volume":"83","author":"Jelkmann","year":"2004","journal-title":"Annals of Hematolology"},{"issue":"1","key":"10.1002\/14651858.CD003407.pub5-BIB0614|cit614","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.critrevonc.2008.03.006","article-title":"The erythropoietin receptor in normal and cancer tissues","volume":"67","author":"Jelkmann","year":"2008","journal-title":"Critical Reviews in Oncology\/Hematology"},{"issue":"10","key":"10.1002\/14651858.CD003407.pub5-BIB0615|cit615","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/ajh.21805","article-title":"Biosimilar epoetins and other \"follow-on\" biologics: update on the European experiences","volume":"85","author":"Jelkmann","year":"2010","journal-title":"American Journal of Hematology"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0616|cit616","unstructured":"Johnson & Johnson Pharmaceutical Research & Development L.L.C Safety of Erythropoietin Receptor Agonists (ERAs) in Patients With Cancer Background Information For Oncologic Drugs Advisory Committee Meeting. May 4 2004"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0617|cit617","first-page":"109","article-title":"In vivo supression of erythropoiesis by tumor necrosis factor-alpha (TNF-alpha): Reversal with exogenous erythropoietin (EPO)","volume":"18","author":"Johnson","year":"1990","journal-title":"Experimental Hematology"},{"issue":"4","key":"10.1002\/14651858.CD003407.pub5-BIB0618|cit618","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/bjc.1993.417","article-title":"The effect of recombinant human erythropoietin treatment on tumour radiosensitivity and cancer-associated anaemia in the mouse","volume":"68","author":"Joiner","year":"1993","journal-title":"Brirish Joural of Cancer"},{"issue":"8","key":"10.1002\/14651858.CD003407.pub5-BIB0619|cit619","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1002\/cncr.20569","article-title":"Epoetin alfa improves quality of life in patients with cancer: results of metaanalysis","volume":"101","author":"Jones","year":"2004","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0620|cit620","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1345\/aph.1A416","article-title":"Darbepoetin alfa: a novel erythropoiesis-stimulating protein","volume":"36","author":"Joy","year":"2002","journal-title":"Annals of Pharmacotherapy"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0621|cit621","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1001\/jama.282.11.1054","article-title":"The hazards of scoring the quality of clinical trials for meta-analysis","volume":"282","author":"J\u00fcni","year":"1999","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0622|cit622","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/bmj.323.7303.42","article-title":"Assessing the quality of controlled clinical trials","volume":"323","author":"J\u00fcni","year":"2001","journal-title":"BMJ"},{"issue":"Suppl IV","key":"10.1002\/14651858.CD003407.pub5-BIB0623|cit623","first-page":"20","article-title":"Can erythropoietin improve tumor oxygenation?","volume":"174","author":"Kelleher","year":"1998","journal-title":"Strahlentherapie und Onkologie"},{"issue":"1","key":"10.1002\/14651858.CD003407.pub5-BIB0624|cit624","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1524-4733.2007.00215.x","article-title":"Does epoetin alfa improve health-related quality of life in chronically ill patients with anemia? Summary of trials of cancer, HIV\/AIDS, and chronic kidney disease","volume":"11","author":"Kimel","year":"2008","journal-title":"Value in Health : the journal of the International Society for Pharmacoeconomics and Outcomes Research"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0625|cit625","doi-asserted-by":"crossref","first-page":"11S","DOI":"10.1016\/j.amjmed.2003.12.008","article-title":"Prevalence and outcomes of anemia in cancer: a systematic review of the literature","volume":"116 Suppl 7A","author":"Knight","year":"2004","journal-title":"The American Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD003407.pub5-BIB0626|cit626","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0167-8140(99)00139-5","article-title":"Intratumoral pO2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix","volume":"53","author":"Knocke","year":"1999","journal-title":"Radiotherapy and Oncology"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0627|cit627","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/j.1875-9114.1998.tb03834.x","article-title":"Clinical guidelines for the treatment of cancer-related anemia","volume":"18","author":"Koeller","year":"1998","journal-title":"Pharmacotherapy"},{"issue":"4","key":"10.1002\/14651858.CD003407.pub5-BIB0628|cit628","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/bjc.1991.119","article-title":"The influence of chronic anaemia on the radiosensitivity of two mouse tumours","volume":"63","author":"Koong","year":"1991","journal-title":"Brirish Journal of Cancer"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0629|cit629","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1182\/blood.V71.2.524.524","article-title":"Localization of erythropoietin synthesizing cells in murine kidneys by in situ hybridization","volume":"71","author":"Koury","year":"1988","journal-title":"Blood"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0630|cit630","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1046\/j.1537-2995.1990.30891020321.x","article-title":"Control of red cell production: the roles of programmed cell death (apoptosis) and erythropoietin","volume":"30","author":"Koury","year":"1990","journal-title":"Transfusion"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0631|cit631","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1182\/blood.V77.11.2497.2497","article-title":"Localization of cells producing erythropoietin in murine liver by in situ hybridization","volume":"77","author":"Koury","year":"1991","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0632|cit632","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006158.pub2","article-title":"Erythropoietin as an adjuvant treatment with (chemo) radiation therapy for head and neck cancer","author":"Lambin","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0633|cit633","first-page":"187","article-title":"Blood transfusion-induced immunomodulation","volume":"82","author":"Landers","year":"1996","journal-title":"Anesthesia and Analgesia"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0634|cit634","unstructured":"Lefebvre C Manheimer E Glanville J Chapter 6: Searching for studies. Higgins JPT Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (update March 2011). 2011"},{"issue":"24","key":"10.1002\/14651858.CD003407.pub5-BIB0635|cit635","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJM199006143222402","article-title":"Erythropoietin treatment of anemia associated with multiple myeloma","volume":"322","author":"Ludwig","year":"1990","journal-title":"New England Journal of Medicine"},{"issue":"3 Suppl 7","key":"10.1002\/14651858.CD003407.pub5-BIB0636|cit636","first-page":"2","article-title":"Anemia in cancer patients","volume":"25","author":"Ludwig","year":"1998","journal-title":"Seminars in Oncology"},{"issue":"2, Suppl 8","key":"10.1002\/14651858.CD003407.pub5-BIB0637|cit637","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0093-7754(01)90206-4","article-title":"Symptomatology of anemia","volume":"28","author":"Ludwig","year":"2001","journal-title":"Seminars in Oncology"},{"issue":"17","key":"10.1002\/14651858.CD003407.pub5-BIB0638|cit638","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1200\/JCO.2008.19.1130","article-title":"Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia","volume":"27","author":"Ludwig","year":"2009","journal-title":"Journal of Clinical Oncology : official journal of the American Society of Clinical Oncology"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0639|cit639","unstructured":"Luksenburg H Weir A Wager R Safety Concerns Associated with Aranesp (darbepoetin alfa) Amgen, Inc. and Procrit (epoetin alfa) Ortho Biotech, L.P., for the Treatment of Anemia Associated with Cancer Chemotherapy FDA Briefing Document May 4, 2004 Oncologic Drugs Advisory Committee 2004"},{"issue":"2","key":"10.1002\/14651858.CD003407.pub5-BIB0640|cit640","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0049-3848(95)91619-V","article-title":"A study of platelet functions, some hemostatic and fibrinolytic parameters in relation to serotonin in hemodialyzed patients under erythropoietin therapy","volume":"77","author":"Malyszko","year":"1995","journal-title":"Thrombosis Research"},{"issue":"9","key":"10.1002\/14651858.CD003407.pub5-BIB0641|cit641","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.yexcr.2011.03.003","article-title":"Erythropoietin for oncology supportive care","volume":"317","author":"McKinney","year":"2011","journal-title":"Experimental Cell Research"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0642|cit642","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1053\/ctrv.2000.0181","article-title":"Anaemia in cancer: pathophysiology and treatment","volume":"26","author":"Mercadante","year":"2000","journal-title":"Cancer Treatment Reviews"},{"issue":"16","key":"10.1002\/14651858.CD003407.pub5-BIB0643|cit643","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1093\/jnci\/djn250","article-title":"A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue","volume":"100","author":"Minton","year":"2008","journal-title":"Journal of the National Cancer Institute"},{"issue":"7","key":"10.1002\/14651858.CD003407.pub5-BIB0644|cit644","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006704.pub3","article-title":"Drug therapy for the management of cancer-related fatigue","author":"Minton","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9263","key":"10.1002\/14651858.CD003407.pub5-BIB0645|cit645","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S0140-6736(00)04337-3","article-title":"The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials","volume":"357","author":"Moher","year":"2001","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0646|cit646","first-page":"178","article-title":"Tumor anemia. Overview of the role of human recombinant erythropoietin (r-hu-EPO)in treatment of tumor anemia (in German)","volume":"88","author":"Monnerat","year":"1999","journal-title":"Schweizerische Rundschau f\u00fcr Medizin"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0647|cit647","first-page":"21","article-title":"Epoetin and cognitive function","volume":"20","author":"Nissenson","year":"1992","journal-title":"American Journal of Kidney Diseases"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0648|cit648","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0167-8140(96)91811-3","article-title":"Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck","volume":"41","author":"Nordsmark","year":"1996","journal-title":"Radiotherapy Oncology"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0649|cit649","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/978-3-7091-7658-0_3","article-title":"Pathophysiology of cancer-related anemia","volume-title":"Recombinant HumanErythropoietin (rhEPO) in Clinical Oncology","author":"Nowrousian","year":"2002"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0650|cit650","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/978-3-7091-7658-0_4","article-title":"Prevalence, pathophysiology, predictive factors, and prognostic significance of anemia in cancer chemotherapy","volume-title":"Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology","author":"Nowrousian","year":"2002"},{"issue":"1","key":"10.1002\/14651858.CD003407.pub5-BIB0651|cit651","doi-asserted-by":"crossref","first-page":"23","DOI":"10.7326\/0003-4819-153-1-201007060-00252","article-title":"Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease","volume":"153","author":"Palmer","year":"2010","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0652|cit652","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0653|cit653","unstructured":"Quirt I Micucci S Moran LA Pater J Browman G The role of erythropoietin in the management of cancer patients with non-hematologic malignancies receiving chemotherapy Cancer Care Ontario Practice Guidelines Initiative"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0654|cit654","unstructured":"Quirt I Bramwell V Charette M Oliver T and the Systemic Treatment Disease Site Group The role of erythropoietin in the management of cancer patients with non-hematologic malignancies receiving chemotherapy. Practice Guideline Report #12-1 program in evidence-based care; a cancer care ontario program 2005 2526"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0655|cit655","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/00000441-199407000-00004","article-title":"Implications of the anemia of chronic disorders in patients anticipating radiotherapy","volume":"308","author":"Reed","year":"1994","journal-title":"American Journal of the Medical Sciences"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0656|cit656","unstructured":"ROCHE NEORECORMON (EPOETIN BETA) Briefing Package for the FDA Oncologic Drugs Advisory Committee Meeting May 4, 2004"},{"issue":"6","key":"10.1002\/14651858.CD003407.pub5-BIB0657|cit657","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1016\/S0149-2918(03)80170-4","article-title":"The effect of anemia treatment on selected health-related quality-of-life domains: a systematic review","volume":"25","author":"Ross","year":"2003","journal-title":"Clinical Therapeutics"},{"issue":"6","key":"10.1002\/14651858.CD003407.pub5-BIB0658|cit658","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.clinthera.2006.06.003","article-title":"Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature","volume":"28","author":"Ross","year":"2006","journal-title":"Clinical Therapeutics"},{"issue":"10","key":"10.1002\/14651858.CD003407.pub5-BIB0659|cit659","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1634\/theoncologist.12-10-1264","article-title":"Efficacy and safety of erythropoiesis-stimulating proteins in myelodysplastic syndrome: a systematic review and meta-analysis","volume":"12","author":"Ross","year":"2007","journal-title":"The Oncologist"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0660|cit660","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"issue":"16","key":"10.1002\/14651858.CD003407.pub5-BIB0661|cit661","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/jnci\/93.16.1204","article-title":"Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials","volume":"93","author":"Seidenfeld","year":"2001","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0662|cit662","unstructured":"Seidenfeld J Aronson N Piper MA Flamm C Hasselblad V Ziegler KM Uses of erythropoietin for anemia in oncology Evidence report\/technology assessment No. 30. Prepared by the Blue Cross and Blue Shield Association Evidence-based Practice Center, 2001 Agency for Healthcare Research and Quality"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0663|cit663","unstructured":"Seidenfeld J Piper M Bohlius J Weingart O Trelle S Engert A Comparative effectiveness of epoetin and darbepoetin for managing anemia in patients undergoing cancer treatment Agency for Healthcare Research and Quality 2006 N\/A"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0664|cit664","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1006\/gyno.1999.5368","article-title":"Effects of recombinant human erythropoietin on the antitumor effect of cisplatin in SCID mice bearing human ovarian cancer: A possible oxygen effect","volume":"73","author":"Silver","year":"1999","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0665|cit665","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1182\/blood.V84.4.997.997","article-title":"Recombinant human erythropoietin and the anemia of cancer","volume":"84","author":"Spivak","year":"1994","journal-title":"Blood"},{"issue":"2, Suppl 3","key":"10.1002\/14651858.CD003407.pub5-BIB0666|cit666","first-page":"3","article-title":"Cancer-related anemia: its causes and characteristics","volume":"21","author":"Spivak","year":"1994","journal-title":"Seminars in Oncology"},{"issue":"2","key":"10.1002\/14651858.CD003407.pub5-BIB0667|cit667","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0049-3848(02)00011-7","article-title":"Erythropoietin and granulocyte colony-stimulating factor increase plasminogen activator inhibitor-1 release in HUVEC culture","volume":"105","author":"Stasko","year":"2002","journal-title":"Thrombosis Research"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0668|cit668","unstructured":"Sterne JAC Egger M Moher D Chapter 10: Addressing reporting biases Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions, version 5.1.0 (updated March 2011) 2011"},{"issue":"9","key":"10.1002\/14651858.CD003407.pub5-BIB0669|cit669","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1182\/blood.V95.9.2983.009k27_2983_2989","article-title":"Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans","volume":"95","author":"Stohlawetz","year":"2000","journal-title":"Blood"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0670|cit670","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1046\/j.1365-2141.1998.00521.x","article-title":"Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties","volume":"100","author":"Storring","year":"1998","journal-title":"British Journal of Haematology"},{"issue":"10","key":"10.1002\/14651858.CD003407.pub5-BIB0671|cit671","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1080\/09553000601002324","article-title":"Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy","volume":"82","author":"Tatum","year":"2006","journal-title":"International Journal of Radiation Biology"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0672|cit672","first-page":"73","article-title":"Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells","volume":"41","author":"Teicher","year":"1981","journal-title":"Cancer Research"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0673|cit673","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/BF00689633","article-title":"Hypoxia and drug resistance","volume":"13","author":"Teicher","year":"1994","journal-title":"Cancer Metastasis Reviews"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0674|cit674","first-page":"1358","article-title":"Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors","volume":"61","author":"Thews","year":"2001","journal-title":"Cancer Research"},{"issue":"Supp 1","key":"10.1002\/14651858.CD003407.pub5-BIB0675|cit675","first-page":"3","article-title":"Impact of anemia and fatigue on quality of life in cancer patients: a brief review","volume":"15","author":"Thomas","year":"1998","journal-title":"Medical Oncology"},{"issue":"11","key":"10.1002\/14651858.CD003407.pub5-BIB0676|cit676","doi-asserted-by":"crossref","first-page":"E62","DOI":"10.1503\/cmaj.090470","article-title":"Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis","volume":"180","author":"Tonelli","year":"2009","journal-title":"CMAJ"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0677|cit677","unstructured":"Tonelli M Lloyd A Lee H Wiebe N Hemmelgarn B Reiman T Erythropoiesis-stimulating agents for anemia of cancer or of chemotherapy: systematic review and economic evaluation [Technology report number 119]. Ottawa: Canadian Agency for Drugs and Technologies in Health; Ottawa: Canadian 2009 N\/A"},{"issue":"1","key":"10.1002\/14651858.CD003407.pub5-BIB0678|cit678","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1040-8428(03)00093-3","article-title":"Impact of haemoglobin levels on the outcome of cancers treated with chemotherapy","volume":"47","author":"Belle","year":"2003","journal-title":"Critical Reviews in Oncology\/Hematology"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0679|cit679","first-page":"6449","article-title":"Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review","volume":"49","author":"Vaupel","year":"1989","journal-title":"Cancer Research"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0680|cit680","first-page":"869","article-title":"Blood supply, oxygenation status and metabolic micromilieu of breast cancers: Characterization and therapeutic relevance","volume":"17","author":"Vaupel","year":"2000","journal-title":"International Journal of Oncology"},{"issue":"2","key":"10.1002\/14651858.CD003407.pub5-BIB0681|cit681","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0093-7754(01)90210-6","article-title":"Oxygen status of malignant tumors: Pathogenesis of hypoxia and significance for tumor therapy","volume":"28","author":"Vaupel","year":"2001","journal-title":"Seminars in Oncology"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0682|cit682","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1634\/theoncologist.13-S3-21","article-title":"Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis","volume":"13 Suppl 3","author":"Vaupel","year":"2008","journal-title":"The Oncologist"},{"issue":"12","key":"10.1002\/14651858.CD003407.pub5-BIB0683|cit683","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/S0895-4356(98)00131-0","article-title":"The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus","volume":"51","author":"Verhagen","year":"1998","journal-title":"Journal of Clinical Epidemiology"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0684|cit684","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with Metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"Journal of Statistical Software"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0685|cit685","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1136\/bmj.319.7201.16","article-title":"Serious hazards of transfusion (SHOT) initiative: analysis of the first two annual reports","volume":"319","author":"Williamson","year":"1999","journal-title":"BMJ"},{"issue":"13","key":"10.1002\/14651858.CD003407.pub5-BIB0686|cit686","first-page":"1-202, iii-iv","article-title":"A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment","volume":"11","author":"Wilson","year":"2007","journal-title":"Health technology assessment (Winchester, England)"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0687|cit687","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1172\/JCI117840","article-title":"Cisplatin-associated anemia: an erythropoietin deficiency syndrome","volume":"95","author":"Wood","year":"1995","journal-title":"Journal of Clinical Investigation"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0688|cit688","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1093\/carcin\/bgg060","article-title":"Erythropoietin regulates tumour growth of human malignancies","volume":"24","author":"Yasuda","year":"2003","journal-title":"Carcinogenesis"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0689|cit689","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0885-3924(96)00274-6","article-title":"Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system","volume":"13","author":"Yellen","year":"1997","journal-title":"Journal of Pain and Symptom Management"},{"issue":"7","key":"10.1002\/14651858.CD003407.pub5-BIB0690|cit690","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/jnci\/dji087","article-title":"Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis","volume":"97","author":"Bohlius","year":"2005","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1002\/14651858.CD003407.pub5-BIB0691|cit691","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/jnci\/djj189","article-title":"Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients","volume":"98","author":"Bohlius","year":"2006","journal-title":"Journal of the National Cancer Institute"},{"issue":"3","key":"10.1002\/14651858.CD003407.pub5-BIB0692|cit692","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003407.pub4","article-title":"Erythropoietin or Darbepoetin for patients with cancer","author":"Bohlius","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD003407.pub5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T12:08:33Z","timestamp":1729512513000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD003407.pub5"}},"subtitle":[],"editor":[{"name":"Cochrane Haematological Malignancies Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2012,12,12]]},"references-count":692,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2012,12]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd003407.pub5","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,12]]}}}